




Department of Dermatology,
Zurich University Hospital



Biennial Report
2013 – 2014



UniversitätsSpital
Zürich



Universität
Zürich ^{UZH}

content

1. Assignment of the Department of Dermatology Zurich University Hospital
2. Mission Statement
3. Team
4. Patient Care including Laboratories
5. Quality Management
6. Research
7. University Research Priority Project (URPP)
Translational Oncology
8. New Clinician-Scientists and Scientists
9. Clinical research: The Zurich University Hospital
Dermatology Clinical Trial Unit
10. Research Foundations
11. Medical Education / Teaching
12. Museum of Wax Moulages
13. Honoraries and Prizes
14. Partners/Sponsors/Collaboration with Industry and
Fund Raising
15. Publications



Biennial Report 2013 – 2014

Foreword

Dear Colleagues, friends, referring physicians, patients, partners and readers. It is my pleasure, in the name of my team of collaborators at the Department of Dermatology of the Zurich University Hospital, to provide you with an update of our recent activities within this biennial report.

Our department has set itself the aim of providing top quality patient care, research and education in the fields of dermatology, venerology and allergology, with a priority on innovation and leadership in dermatology, immuno-dermatology and allergology.

The time frame covered by this biennial report represents my 7th and 8th years chairing the Department. It reflects a period of perceptible increase in health-economic pressure, efforts to further improve efficiency and optimize processes of patient care without compromising high-level standards in ethics, teaching, quality of care and research.

In the last 2 years we have invested great effort into the in house promotion and recruitment and of talented clinicians, clinician-scientists and scientists as future leaders to further strengthen the Department. We have guaranteed the promotion of our focus on cutaneous oncology within a unique University Research Priority Program “Translational Oncology” financed with over 6 million Swiss Francs over 4 years under my direction in collaboration with 11 outstanding physicians and scientists from the University of Zurich (www.cancer.uzh.ch). We are part of an innovative public-private joint research program on cancer with Roche and in collaboration with the Department of Pathology at the Zurich University Hospital and the ETH. Finally we have launched of a priority program to promote inflammatory skin disease research, care and training, and the implementation of a departmental palliative-care program.

Modern infrastructure in healthcare contributes to efficiency and quality of care, as well as patient satisfaction. In an effort to modernize our infrastructure, our light and laser therapy unit was completely rebuilt so as

to now offer optimal patient privacy, and a comfortable as well as practical environment for both our patients and employees. Our employees however are the premier guarantee of quality. In the last 2 years we have greatly profited from the recruitment of a new head of in-patient nursing in the person of Ms. K. Pauli, as well as 2 senior physicians and talented clinician-scientists returning to Europe from a fellowship in Harvard (Dr E. Guenova-Hötzenecker and PD Dr W. Hötzenecker). Likewise we have benefitted from the return of another talented clinician-scientist in the person of PD Dr A. Navarini from a fellowship in genomics and bioinformatics of inflammatory skin diseases at St John's Institute of Dermatology/Kings College London. In 2013, a professorship funded by the “Verein für Hautkrebsforschung” was given to an outstanding scientist in the person of Prof. Mitch Levesque from the group of Prof. R. Dummer who is actively promoting our melanoma research and the development of an innovative Biobank of over 1,000 live primary tumor cell lines linked to genomic and clinical data.

In the same time-period four of our senior physicians (Drs J. Kamarachev, K. Kerl-French, S. Läuchli and W. Hötzenecker) and one senior scientist (Dr H.-D. Beer), were recognized by our University for their academic achievements and awarded the Venia Legendi by the University of Zurich. Also recognized was Prof. M. Maiwald with the reknown Götz Prize of the University of Zurich which honours outstanding, internationally visible academic achievement. In 2013, Prof. M. Maiwald and Prof. G. Hofbauer were both promoted to the status of Titulary Professors at the University of Zurich, and last but not least, Prof. O. Boyman who was an outstanding Swiss national Science Foundation Professor awardee at our Institution, and recipient of the Leo Pharma Research Foundation Gold award for his outstanding research in 2013, was nominated as Professor and Chairman of the Department of Clinical Immunology of the Zurich University Hospital as of 2014. Besides these newly recruited persons and awards, we are also proud of the successful board certification of 11 of our residents in training (Drs S. Gobbi, S. Gisler, A. Moser, M. Theiler, M. Barysch, J. Rinderknecht, C. Murer, M. Nägeli, N. Winterton, P. Dziunycz and R. Kasper).

With over 50 interventional clinical trials running currently in skin cancer and inflammatory skin diseases,



and in the context of an ongoing professionalisation of our clinical trial unit we are very fortunate that one of our board-certified physicians, Dr S. Goldinger, recently successfully completed a second board certification in Pharmaceutical Medicine. This is a rarity for us and a great addition to our Department. Dr Goldinger will be responsible for our clinical trials unit as of April 2015.

thankful, we are ready to take on the next challenges in dermatology research and patient care.

With this selection of significant achievements realized in 2013–2014, I invite you in the name of my entire team to discover more in the following pages. Enjoy!

2013 was also a special year for the Departments Bruno Bloch Foundation which strives to raise money for supporting research and education in the Department. On the 7th of November 2013, the Foundation was able to raise 225,000 Swiss Francs as the result of a gala concert that it organized in the Zurich Tonhalle with the outstanding musicians Anne-Sophie Mutter and Lambert Orkis. The Department and the Bruno Bloch Foundation are extremely grateful to the above artists, the generous participants and donators for their generous support.



Prof. Dr med. Lars E. French
Chairman Department of Dermatology
University Hospital Zurich

Finally and in 2014, the Department had the honor of hosting in Zurich and under the direction of Prof. R. Dummer and his team the Annual Meeting of the Society for Melanoma Research. The meeting was a great success with over 1,000 attendees and the presentation of outstanding innovative data, some of which was published the day after presentation in the New England Journal of Medicine!

The significant developments in our Department that I have highlighted in this “Foreword” give me confidence that – despite the current times of perceptible increase in health-economic pressure – we can look forward to the coming years with confidence. With an extremely dedicated team of which I am proud and to which I am

1. Assignment of the Department of Dermatology Zurich University Hospital

The Department of Dermatology of the Zurich University Hospital is devoted to provide sustained leadership in research, patient care and education in the fields of dermatology, venerology and allergology.

Our nationally and internationally recognized Department includes centers of excellence for skin cancer, inflammatory and allergic skin diseases as well as dermatological surgery. With a team of 47 specialized physicians we offer high-level patient care in all areas of dermatology, venerology and allergology in the context of our large out-patient ambulatory care clinic (Dermatologische Poliklinik), our in-patient dermatology service, our day care unit, and tertiary care referral clinics in a large number of specialty areas. These include: melanoma and difficult pigmented lesions, non-melanoma skin cancers, cutaneous lymphoma, bullous and autoimmune skin disease, medical dermatology, psoriasis, hair and scalp disease, occupational and contact dermatitis, dermatologic surgery, dermatopathology, and physical therapies (phototherapy, radiotherapy and laser therapy). Our research activities are focussed on basic and translational research with relevance to skin disease, primarily skin cancer and inflammatory skin disease. The efforts of our research groups are reflected by regular high level publications and a high cumulative yearly impact factor. Collaboration and networking with talented scientists and research groups within the University of Zurich, the ETH, collaborative networks such as the Zurich Cancer network, and other leading European Dermatology Centers considerably strengthens our research activities. Education is the third principle field of activity of our Department. In the past few years, the Department has focussed its resources on pre- and post-graduate training as well as on the development and maintenance of our innovative internetbased pre-graduate learning tool – DOIT (Dermatology Online with Interactive Technology in collaboration with the European Dermatology Forum).





2. Mission Statement


The top priorities of the Department of Dermatology USZ – in close collaboration with other Departments and Institutes of the USZ – are:

- to offer high quality individualized diagnosis and therapy of skin disease, as well as patient education in skin care and prevention of skin disease.
- to provide a high level of teaching and training in dermatology at the pre- and post-graduate level.
- to perform innovative basic and clinical research with the ultimate aim of contributing to improved patient-care.
- to foster constructive collaboration and networks with private practitioners as well as primary and secondary institutional care providers.

By fulfilling this mission we aim to position our department among the leading Dermatology Departments in Europe.

3. Team

The department of Dermatology has a staff of 168 people including medical doctors, nursing staff, medical technical staff, laboratory staff, administrative staff and 40 research collaborators. Routinely, our Department hosts fellows and guests from abroad within its clinical and research activities.



Laboratory staff

DERMATOLOGISCHE KLINIK



UniversitätsSpital
Zürich

DIRECTION OF THE DEPARTMENT
"KLINIKLEITUNG"
DEPARTMENT OF DERMATOLOGY


Klinikdirektor



Prof. Dr. med.
Lars E. French

Stv. Klinikdirektor

Dermatoonkologie / Klinische Forschung /
Physikalische Therapie



Prof. Dr. med.
Reinhard Dummer

Leitung Pflege




Tina Plötz

Klinikmanager



Marianne Anliker

Leitende Ärzte/innen



Oberärzte/innen



USZ-Anstellung

UZH-Anstellung

FACULTY
DEPARTMENT OF DERMATOLOGY

4. Patient Care including Laboratories

In the Swiss Health Service, inpatient dermatology is virtually exclusively available at the five university hospitals. In contrast, ambulatory care is offered both in the private sector and the public setting of university and state hospitals. As the largest academic dermatology center in Switzerland, the Department of Dermatology at the University of Zurich offers state of the art in-patient medical care for complex and rare skin problems. The department has very skilled surgeons that can perform complex surgical procedures and also histologically controlled procedures. In addition, our department is able to administer complex chemotherapeutic regimens or intravenous immunotherapy including antibodies and fusion molecules. Moreover, we provide an extensive spectrum of out-patient services including highly specialized consultations. Our department benefits from a large area referral base for these specialized activities as well as its own on-site histopathology laboratory.

Out-patient unit (Policlinic) & specialized ambulatory care clinics

PD Dr A. Cozzio and his team of dermatologists and specialized nurses treat over 30,000 patients upon referral in a total of over 72,000 consultations per year. In addition to the general out-patient clinics, patients can profit from international experts in their fields of dermatology and venereology in specialized out-patient clinics for autoimmune disorders, psoriasis, atopic eczema, acne and other severe dermatologic diseases.

In the day care clinic, a specialized team of doctors and nurses within the out-patient clinic treat patients with severe dermatologic diseases such as melanoma, cutaneous lymphoma, severe psoriasis, or autoimmune disorders. This innovative treatment center offers established infusion and injection treatments for these diseases, and, given its proximity to the clinical trial unit of the dermatology department, also performs up-to-date chemotherapeutic and immunologic anti-tumour treatments which have recently proven to be highly effective against melanoma and other skin cancers such as cutaneous lymphoma. This in-house interaction with one of the world-known research centers for skin cancers proves highly useful for rapid access to, and handling knowledge with medications with higher therapeutic efficacy in these diseases.

Certified Skin Tumor Center (Schwerpunkt Hautkrebs)

Our skin cancer center runs under the direction of Prof. R. Dummer with a team of expert skin cancer specialists (Prof. R. Braun, Prof. G. Hofbauer, PD Dr A. Cozzio, Prof. Dr M. Maiwald and Dr S. Goldinger), and is comprised of the following clinics. The pigmented lesion & skin cancer prevention clinic: this clinic runs under the direction of Prof. R. Braun and makes use of the most modern high tech equipment (confocal microscopy, skin surface videomicroscopy, dermoscopy, total body imaging) for the early detection of melanoma. The skin cancer clinic runs under the direction of Prof. R. Dummer and offers patients with skin cancer of different types (melanoma and non-melanoma skin cancer) highly professionalized treatment and follow-up as well as access to the most innovative clinical trials. The cutaneous lymphoma clinic runs under the direction of PD Dr A. Cozzio. In the above specialized clinics of our skin cancer center, patients have access to the best standards of diagnosis and care, a multi-disciplinary approach with tumor boards where required, and a broad variety of treatments including:



surgical interventions, physical treatment with special light sources or radiotherapy, photopheresis, topical immunomodulatory treatments, targeted cancer therapies and chemotherapy. Patients with certain types of cancer, especially melanoma are offered to have a molecular sub typing of their malignancy that is the basis for the selection of specific targeted therapies, such as Vemurafenib or Imatinib. These molecules have high response rates, even in metastatic melanoma. The Skin Cancer Center is supported by a world class clinical trial unit. This clinical trial unit is performing phase I, II and III trials. Most of them are international trials sponsored by pharmaceutical companies. The clinical trial unit plays a central role in the development of the second generation BRAF inhibitors and the second generation smoothened inhibitors. It was also the first clinical trial unit that used immune-modifying antibodies such as ipilimumab and very recently anti-PD 1 antibodies in the clinic in Switzerland. In the context of kinase inhibitors there are very recent data that suggest that MEK kinase inhibitors are powerful therapeutics in NRAS mutated metastatic melanoma. Innovative treatments are also investigating the use of topical substances such as resiquimod.

Investigator-initiated trials are very important tools to improve the data sets relevant for evidence-based medicine. In close cooperation with the EORTC, there were two investigator-initiated international trials in primary cutaneous T-cell lymphomas (mycosis fungoides), one for early stages comparing PUVA-therapy to a combination of PUVA and bexarotene and one for advanced stages investigating pegylated liposomal doxorubicin in tumor stage mycosis fungoides. Both trials finally have been closed successfully, and the intriguing results are available as decent publications.

Our inflammatory skin disease research group has been involved in several international trials sponsored by pharmaceutical companies too. Among molecules tested in psoriasis are antibodies against IL-17 and IL-17 receptor as well as small molecules targeting S1P1 and phosphodiesterase 4. Several innovative investigator-initiated trials are also being conducted in pyoderma gangraenosum, chronic urticaria and mastocytosis.

The ongoing clinical trials can be found on our website (<http://www.dermatologie.usz.ch/HealthProfessionals/studien/Seiten/AktuelleStudien.aspx>). On this link there are also listed the publications on our clinical research work.

Allergology Unit

The allergology unit of our department is a European certified (GALEN) center of excellence specialized in the diagnosis and treatment of acute and chronic allergic disease. Managed by Prof. P. Schmid and Prof. B. Ballmer-Weber, our allergy unit has developed a special focus on skin allergy, food allergy, drug allergy and desensitization protocols (specific immunotherapy), for example for life-threatening insect sting allergies.

Surgery Unit

Our surgical unit and its experienced team of dermatological surgeons (PD Dr S. Läubli and Prof. J. Hafner) have developed a renown activity in general dermatological surgery with a focus on skin cancer surgery and chronic wound surgery. High-end techniques such as micrographic surgery (MOHS) for complex skin cancer cases, ablative laser treatments or fibrotic tissue shaving and skin transplantation for complex wounds are regularly performed with a high level of patient satisfaction in this unit.

Physical Treatment Unit – including Radiotherapy, Phototherapy & Laser Unit

This unit led by Prof. R. Dummer, Prof. G. Hofbauer and Dr L. Imhof is equipped with the latest physical therapy technologies, including UVA1 devices and a full laser and Intense Pulsed Light (IPL) platform. Recently, two modern X ray devices for superficial radiotherapy of skin cancer and selected refractory inflammatory diseases has been installed.

Over 3,000 treatments are performed per year.

The Department of Dermatology has a long-lasting interest in the application of laser technology. The Laser & Cosmetic therapy unit attracts patients from all over the world seeking treatment for cosmetic and skin conditions. We perform a full range of laser procedures, such as permanent hair removal, tattoo removal, laser treatments of vascular disorders, fractional resurfacing, fractional CO₂ and fractional erbium treatments, skin-tightening procedures and traditional CO₂ and erbium-resurfacing treatments. Additionally we perform numerous other treatments such as injections with botulinumtoxin, soft tissue fillers and chemical peels. In the last year under the direction of Dr L. Imhof the first study was performed comparing efficacy and safety of a Q-switched laser to a triple combination skin lightening cream in the treatment of solar lentigines. Dr L. Imhof collaborates with the Physics Institute of the ETH to further investigate the interaction of laser light and human skin tissue, and in an interdisciplinary manner with the plastic surgeons in the management of scar patients especially with burn scars.

Weekday in-patient ward

Our weekday in-patient ward under the direction of Prof. G. Hofbauer with a specialized multidisciplinary team of doctors and nurses provides a unique setting for complex topical or systemic therapy of refractory skin diseases, including the infusion of biologicals and chemotherapies. The team has 10 beds to provide rapid, complex in-patient workups and short in-patient therapies. This concept developed in 2007 has been highly successful and associated with a significant reduction in our overall mean length of in-patient hospital stay. This unit also offers extracorporeal photopheresis, an immunomodulatory treatment, to stem cell transplant recipients with graft-versus-host-disease, to lung transplant recipients suffering organ rejection, and to cutaneous lymphoma patients with three photopheresis units.

In-patient clinic

Our in-patient clinic with 26 beds, 8 of which are available for semi-private and privately insured patients is unique with respect to the medical expertise and the level of integrated medical and dermatological care that the highly specialized but also uniquely caring team of nurses and doctors offers. Under the direction of senior medical staff (Prof. L. French, Prof. R. Dummer, Prof. J. Hafner, Dr K. Schad) solutions are found for the management of the most severe forms of skin disease including complex autoimmune skin disease, skin cancer, therapy resistant atopic dermatitis and complex clinical presentations of skin disease for which an appropriate diagnostic and therapeutic approach needs to put in place. The concentrated medical expertise and friendly atmosphere makes this in-patient unit unique in its kind and regularly appraised by patients.

Reorganization of dermatology nursing care

Current and future circumstances have and will demand greater performance of all staff using fewer resources. Performance indicators and employee reviews have identified the need for action.

Although synergies available through the various capacity factors at the DER E week clinic and DER D in-patient ward were exploited, the measures were not sufficient.

Furthermore, the need for action is intensified due to the fact that nursing staff is in short supply. As a result, new models had to be developed to retain these employees at different stages in their lives.

Both of the existing teams underwent a fundamental rethinking with respect to leadership structure, change management, staff-friendly employment terms, professional and quality assurance and development. The aim of the reorganization was to prepare the DER D and DER E teams to meet the requirements of the service mandate under the leadership of a departmental nursing director, taking into consideration maximum efficiency nursing and effectiveness.

In particular, this required the existing teams to be less rigidly defined and cross-generation diversity management to be pursued in conjunction with the option of flexible staff shift schedules, such as those made possible by rotations.

Staff found these changes to be supportive and enriching to their working environment.

The deployment of technical experts/issue-specific specialists and a nursing expert enabled professional quality to be assured and transient decreases in quality to be identified in good time. This included regular palliative care meetings, case supervision, nursing care meetings, mandatory further education sessions as part of the implementation concept, and monthly training sessions to develop professional skills.

Professional development and quality assurance were continuously assessed and refined by systematically reviewing quality indicators such as CIRS reports, damage incident reports, vigilance reports, infection reports, fall events and patient feedback from the "We value your opinion" forms.

Dermatopathology

Essential for quality of the main focus of our clinical activities



Dermatooncology

- Center of Reference for Melanoma
- Center of Reference for Cutaneous Lymphoma
- MOHS (Micrographic Surgery of Skin Tumors)

Immunodermatology

Statistics: Number of biopsies per year since 2012 – 2014

	2012	Δ 2011 %	2013	Δ 2012 %	2014	Δ 2013 %
Biopsies	28435	+ 0%	29316	+ 3%	30469	+ 4%

At the same time, several employees were trained to regularly work in the area of photopheresis at DER E, which had occasionally been difficult to arrange prior to the reorganization, either because there was no clear general framework in place or because there was relatively little interest among staff. Thanks to intensive staff training, the creation of staff-friendly general conditions and the integration of staff into process optimization activities, it was possible to bring about considerable improvement and introduce a degree of continuity in patient monitoring in conjunction with the facilitation of professional and qualitative development.

Laboratory facilities

The laboratory facilities of the department include labs devoted to routine lab procedures, and labs devoted to research. The department manages fully equipped dermatopathology, allergology, mycology, serology / venereology and 8 competitive skin disease and allergy research laboratories.

Dermatopathology

Our dermatopathology team examines and diagnoses 30,000 samples per year, provides testing of samples for formalin-fixed tissue and cryomaterial (frozen section), as well as specific immunopathological studies (immunohistochemistry, immunofluorescence). In collaboration with other teams we provide molecular biological studies (PCR) for pathogen-search or by suspicion of lymphomas. Our dermatopathology is a certified Teaching Centre and, in collaboration with the European Academy of Dermatology and Venerology (EADV) organises regular courses for residents in dermatology.



Key Figures

	2013	2014	Change %
Hospital leaves - in patient setting (28.7% privately insured patients)	1,332	1,346	1,1%
Days of stay in-patient setting	10,090	10,416	3,2%
Mean Duration of stay of in-patients	6,3	6,5	3,2%
Casemix-Points	1,204	1,216	1,0%
Casemix-Index	0,904	0,904	0,0%
Consultations out-patient setting	73,404	71,834	-2,1%
Tax-points (chargeable)	16,275	16,568	1,8%
Revenues (medical service in mill. CHF)	41,643 mill. CHF	39,951 mill. CHF	
Employes (full-time equivalents)		168	
plus externally funded persons (third-party)		40	



Team Dermatopathology



Other routine laboratories

Besides dermatopathology the clinic is equipped with laboratories devoted to allergology, molecular diagnostics, mycology, and syphilis serology. These labs are run under the head of laboratory Dr P. Bosshard (together with Prof. P. Schmid-Grendelmeier in case of the allergology laboratory) and together analyze 12,000 patient samples per year. The allergology lab is very innovative as it was among the first using ISAC (Immuno Solid-phase Allergen Chip) in Switzerland. In the molecular diagnostics, specialized tests such as the T cell receptor clonality assay or a genital ulcer disease multiplex PCR are performed. The mycology lab is renown as kind of a reference laboratory, especially for dermatophyte infections.

The routine laboratories are currently in the process of being accredited according to ISO 15189:2012.

Research laboratories

The continued expansion of our research activities to now approx. 50 researchers was paralleled with an expansion of our research space. We now operate research laboratories in the top floor of our department at Gloriastr. 31, as well as across the street in Gloriastr. 30, and in 2014 we further expanded to a new campus in Schlieren at the outskirts of Zurich. The latter research campus will over the next years grow to finally house all biomedical research of the Zurich University Hospital. Our labs have all state of the art equipment to perform competitive research in the field of biochemistry, molecular biology, cell biology, immunology and allergy. For animal experiments we have access to a modern animal house at the University Hospital as well as in Schlieren. Our research labs are certified according to ISO standards and, for patient samples, comply with GMP guidelines. Yearly audits take place.

Interdisciplinarity within USZ

Several dermatologic disorders are associated with involvement of other vital organs, and thus best managed in a collaborative and interdisciplinary manner. Regular tumor boards, collaboration with the plastic surgeons and other departments of the USZ as well as immunology and rheumatology joint rounds contribute to guaranteeing an optimal standard of care.

5. Quality Management

Main Fields of activity

Our aim is to ensure that our organization and our services are consistent and of best possible quality. Our activities can be divided in the following four main components: quality planning, quality control, quality assurance and quality improvement. Our activities are not only focused on service quality, but also the means to achieve it. Our quality management therefore uses quality assurance and control of processes such as PDCA (plan-do-check-act or plan-do-check-adjust) to achieve more consistent quality. In order to achieve this goal, we intentionally chose a multidisciplinary approach in order to reach out to all groups of professions and to break barriers between those groups.

Our main focus of interest is the permanent improvement of the quality of care, the safety of our patients, and the satisfaction of our collaborators, referring physicians and most importantly patients.

In a recent enquiry we have asked more than 350 patients about their opinion, 97 % of all Patients would recommend us to a friend or a relative and 99,5 % would get treated again at our facility.

We cover topics such as complaint management, Critical Incident Report System (CIRS) and surveys (patients, collaborators and referring physicians) among others. One of the central activities is the analysis and critical appraisal of all processes in the institution. In order to improve the standard of care we introduced a quality manual which is reviewed and updated on a regular basis. We use quality assurance and process control to achieve, maintain and permanently improve the quality of our care. We formulate annual goals, execute and follow up on them using an interdisciplinary approach breaking down barriers and involving all collaborators in this process.

The department is ISO 9001: 2008 certified by Swiss TS since 2011. This certificate does not only cover the Clinic but has been intentionally extended to research, education and our laboratories.

Our skin cancer centre is certified by the Deutsche Krebsgesellschaft (DKG) via Onkozert since 2011.


We are in charge of the certifications but consider the real challenge to make the step from simply fulfilling requirement catalogs to real quality management projects where everyone (collaborators, patients and referring physicians) can feel the improvement.




Team Certification and Accreditation:
Prof. Dr Ralph Braun, Heiko Müller, Valérie Mucedero, Alice Meier

Results of the evaluation of the Department of Dermatology in 2013:

Would you recommend us to a friend or a relative?



Would consider being treated at our institution in the Future?



6. Research




We aim to continuously improve the quality of our service for patients and therefore critically depend on research and innovation. Our department is committed to the highest level of research in dermatology, and our achievement in this field – as judged by the cumulative impact factors for 2013 and 2014 (632 and 561) – positions us amongst the world's leading Departments in the field.

Our research activities are primarily focused on basic, patient-oriented translational, and clinical research in: dermatology, where we focus on the pathogenesis, early diagnosis and molecular targeted treatment of skin cancer, particularly in melanoma, cutaneous lymphoma, and non-melanoma skin cancers. Immunodermatology is also a research focus, especially innate immunity and T-cell biology in inflammatory skin diseases, notably psoriasis, neutrophilic dermatoses, cutaneous drug eruptions, and severe allergic adverse drug reactions. Allergology, emphasizing on drug and food allergies, and specific immunotherapy.

Aim of our research activities

- to promote high quality research with clinical relevance in the defined above mentioned fields of focus.
- intensive networking and collaboration with other institutes and departments at the Zurich University and ETH, as well as through active participation in networks such as the “Cancer Network Zurich” and “life sciences Zurich”.
- to support fellowships abroad in excellent research institutions, and maximize competitive research funding including that from the Swiss National Science Foundation (incl. SNF professorships).
- to create two endowed professorships in our Department in inflammatory skin disease and skin cancer research respectively, with the aim of recruiting or retaining leaders in these research fields to our department.





Key Figures and Highlights

Approximately 40 ongoing clinical trials on new therapeutic approaches in skin disease – corresponding to around 15% of all studies performed at the USZ.

Approximately 80 original and 30 review articles published in peer-reviewed journals in 2013 and 2014. Several high impact publications in interdisciplinary journals, such as:

- Rozati S, et al. Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. J Clin Oncol 2014
- Robert C, et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med. 2014
- McArthur GA, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014

New intellectual property: in the last five years 7 patent applications have been submitted / registered.

SSS Weekend

In 2013 and 2014 we organized our 18th and 19th so called SSS weekend, which stands for Science, Sun and Snow. Approx. 50 our researchers participated at this meeting, which is held in the Schatzalp Hotel in Davos. At this meeting for one and a half days all of our young researchers present their work and update their progress, followed by intense discussions. The meeting also allows for a skiing day, a dinner and an evening cheese fondue, creating an atmosphere for the best possible scientific exchange.

Research Groups



Group Members

Prof. Dr med. Barbara Ballmer-Weber
(group leader)
Dr med. N. Gräni
Dr med. C. Lang
Irene Cuhat

Main Fields of Research

Our research activities are focused on food allergy, in particular pollen related food allergy. We are particularly involved into the identification and molecular characterisation of important cross-reactive allergens, and the development of diagnostic and therapeutic methods based on recombinant allergens. Allergen based or component resolved diagnosis in food allergy is a major topic of our research group. Another important aspect of our research activity is risk assessment in food allergy in regard to genetic modified foods/novel foods but also threshold doses (minimal allergen doses to induce an allergic reaction) of plant and animal food allergens.

Selected References

Ballmer-Weber BK, Fernandez-Rivas M, Beyer K, Defernez M, Sperrin M, Mackie AR, Salt LJ, Hourihane JOB, Asero R, Belohlavkova S, Kowalski M, de Blay F, Papadopoulos NG, Clausen M, Knulst AC, Roberts G, Popov T, Sprickelman AB, Dubakiene R, Vieths S, van Ree R, Crevel R, Mills C. How much is too much? Threshold dose distributions for five food allergens. *J Allergy Clin Immunol.* 2015 Apr;135(4):964-71

Ballmer-Weber BK, Skamstrup Hansen K, Sastre J, Andersson K, Bättscher I, Ostling J, Dahl L, Hanschmann KM, Holzhauser T, Poulsen LK, Lidholm J, Vieths S. Component-resolved in vitro diagnosis of carrot allergy in three different regions of Europe. *Allergy* 2012; 67(6): 758-66

Mackie A, Knulst A, Le TM, Bures P, Salt L, Mills ENC, Malcolm P, Andreou A, Ballmer-Weber BK. High fat food increases gastric residence and thus thresholds for objective symptoms in allergic patients. *Mol Nutr Food Res* 2012; 56:1708-14

Bublin M, Pfister M, Radauer C, Oberhuber C, Bulley S, Dewitt AM, Lidholm J, Reese G, Vieths S, Breiteneder H, Hoffmann-Sommergruber K, Ballmer-Weber BK. Component-resolved diagnosis of kiwifruit allergy with purified natural and recombinant kiwifruit allergens. *J Allergy Clin Immunol.* 2010; 125: 687-94



Group members

PD Dr Hans-Dietmar Beer, PhD (group leader)

Dr Gerhard Strittmatter, PhD
Martha Garstkiewicz, PhD student
Jennifer Sand, PhD student
Serena Grossi, PhD student

Main Fields of Research

We are mainly interested in the role of keratinocytes, the main cell type of the epidermis, in immunity, inflammation and cancer development in the skin. Upon detection of stress signals in the epidermis, such as UVB irradiation, keratinocytes activate the protease caspase-1 resulting in pro-inflammatory cytokine secretion and inflammation. Our research focuses on the molecular mechanisms underlying caspase-1 activation as well as the down-stream events. Since caspase-1 and other family members are central regulators of inflammation and cell death, pathways critically involved in inflammatory skin conditions but also in cancer, research in our group focuses on the identification of novel targets for the treatment of these diseases.


Selected References

Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer HD. Caspase-1: the inflammasome and beyond. *Innate Immun.* 2014, 20, 115-25

Svitlana K, Schäfer M, Ostano P, Chiorino G, Bloch W, Karouzakis L, Gay S, Garrod D, Lefort K, Dotto GP, Beer HD, Werner S. A novel Nrf2-miR-29-desmosocollin 2 axis controls in vivo desmosome formation. *Nature Communications*, 2014; 5:50999

Beer HD, Contassot E, French LE. The inflammasomes in auto-inflammatory diseases with skin involvement. *J Invest Dermatol.* 2014; 134, 1805-10

Sollberger G, Garstkiewicz M, Strittmatter GE, auf dem Keller U, French LE, Beer HD. Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes. *J Invest Dermatol.* 2015; 135, 1395-404



Group Members

Dr sc. nat. Philipp P. Bosshard (group leader)

Dr med. Martin Glatz
Dr sc. nat. Michael Walser
Stephanie Kieliger
Nada Juricevic

Main Fields of Research

Our research activities focus on sexually transmitted diseases (STI) and fungal infections.
Our main interest is in the development and evaluation of diagnostic tests and in clinical and epidemiological studies.

Selected References


Fröhlich Knaute D, Graf N, Lautenschlager S, Weber R, Bosshard PP. Serological response to treatment of syphilis according to disease stage and HIV status. *Clin Infect Dis.* 2012; doi: 10.1093/cid/cis757

Glatz M, Juricevic N, Altwegg M, Bruisten S, Komericki P, Lautenschlager S, Weber R, Bosshard P. A multicenter prospective trial to assess a new real-time polymerase chain reaction for detection of *Treponema pallidum*, *Herpes simplex-1/2* and *Haemophilus ducreyi* in genital, anal and oropharyngeal ulcers. *Clin Microbiol Infect.* 2014 Jun 9. doi: 10.1111/1469-0691.12710

De Respini S, Tonolla M, Pranghofer S, Petrini L, Petrini O, Bosshard PP. Identification of Dermatophytes by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. *Med Mycol.* 2013 Jul;51(5):514-21. doi: 10.3109/13693786.2012.746476. Epub 2012 Dec 11

Kieliger S, Glatz M, Cozzio A; Bosshard PP. Tinea capitis and tinea faciei in the Zurich area – an 8-year survey of trends in the epidemiology and treatment patterns. *J Eur Acad Dermatol Venereol.* 2014 Dec 10. doi: 10.1111/jdv.12908

Bosshard PP, Graf N, Fröhlich Knaute D, Kündig T, Lautenschlager S, Weber R. Response of *Treponema pallidum* Particle Agglutination (TPPA) test titers to treatment of syphilis. *Clin Infect Dis.* 2012; doi:10.1093/cid/cis850



Group Members

Prof. Dr med. Onur Boyman (group leader)

Dr Usriansyah Hadis, PhD
Dr Antonios Kolios, MD
Dr Carsten Krieg, PhD
Dr Rodney Rosalia, PhD
Natalia Arenas Ramirez, PhD student
Noemi Bertel, MD student
Daniela Impellizzieri, PhD student
Céline Kaegi, MD student
Miro E. Raeber, MD student
Janine Woytschak, PhD student
Emerita Ammann Meier

Main Fields of Research

We are interested in approaches harnessing the stimulation of the immune system against cancer, including melanoma, or in dampening harmful immune responses such as seen in inflammatory and autoimmune diseases, including psoriasis, inflammatory bowel disease and type 1 diabetes. One of our research focuses deals with the modification of cytokines for improved immunotherapy.

Selected References

Bouchaud G, Gehrke S, Krieg C, Kolios A, Hafner J, Navarini AA, French LE, Boyman O. Epidermal IL-15R α acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. *J Exp Med.* 2013; 210: 2105-17

Rosalia RA, Arenas-Ramirez N, Bouchaud G, Raeber ME, Boyman O. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. *Curr Opin Chem Biol.* 2014; 23C: 39-46



Group Leader
Prof. Dr med. Ralph Braun

Main Fields of Research

Our main interest is non invasive diagnosis of skin cancer especially malignant melanoma. We use established techniques such as dermoscopy as well as new techniques in vivo laser scanning microscopy, dermoscopy. Due to different international research collaborations our patients benefit directly from the latest technological developments. Detecting skin cancer especially melanoma at early stages offers an unique opportunity to be cured.

Selected References

Braun, R. P., et al. (2012). Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the „gold standard“? *Dermatology*, 224(1), 51 – 58

Balagula, Y., Braun, R. P., et al. (2012). The significance of crystal-line/ chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. *Basal Cell Carcinoma and Atypical Fibroxanthoma: an Unusual Collision Tumor.*, 67(2), 194.e1 – 8. *j.jaad.*2011

Badertscher, N., Rosemann, T., Tandjung, R., & Braun, R. P. (2011). minSKIN Does a multifaceted intervention improve the competence in the diagnosis of skin cancer by general practitioners? Study protocol for a randomised controlled trial. *Trials*, 12(1), 165



Group Members
PD Dr med. Dr. sc. nat. Antonio Cozzio (group leader)
Dr med. Emanuella Guenova-Hötzenecker (group leader)

Wolfram Hötzenecker, MD, PhD
Joanna Mangana, MD
Tabea Koch
Desislava Ignatova, PhD Student
Yung-Tsan Chang, PhD Student


Main Fields of Research

Our research activities focus on Interactions between innate and adaptive immunity in cutaneous inflammation; Pathogenesis and therapy of skin tumours; cutaneous lymphoma & Merkel cell carcinoma; Development of new immune therapies and translational research.

Selected References

Guenova-Hötzenecker E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kim KW, Park JH, Seo JH, Ignatova D, Cozzio A, Levesque MP, Volz T, Köberle M, Kaesler S, Thomas P, Mailhammer R, Ghoreschi K, Schäkel K, Amarov B, Eichner M, Schaller M, Clark RA, Röcken M, Biedermann T. IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. *Proc Natl Acad Sci U S A.* 2015 112(7):2163-8.






IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. *Proc Natl Acad Sci USA*. 2015 112(7): 2163-8

Skabytka Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen KM, Guenova-Hötzenecker E, Demircioglu D, Kempf WE, Volz T, Rammensee HG, Schaller M, Röcken M, Götz F, Biedermann T. Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells. *Immunity*. 2014 41(5): 762-75

Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova-Hötzenecker E, Teague JE, Campbell L, Yawalkar N, Kupper TS, Clark RA. Human Th9 cells are skin-tropic and have autocrine and paracrine pro-inflammatory capacity. *Sci Transl Med* 2014 6(219): 219ra8

Guenova-Hötzenecker E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaeckel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA. Th2 cytokines from malignant cells suppress Th1 responses and enforce a global Th2 bias in leukemic cutaneous T-cell lymphoma. *Clin Cancer Res*. 2013 19(14): 3755-63



Group Members

Prof. Dr med. Lars E. French (group leader)
 Dr sc. nat. Emmanuel Contassot (principal investigator)
 Dr med. Dr sc. nat. Atsushi Otsuka
 Dr sc. nat. Dragana Jankovic
 Dr sc. nat. Magdalena Kistowska
 Samuel Gehrke (PhD student)
 Roman Huber (PhD student)
 Gabriele Fenini (PhD student)
 Tatiana Proust (Lab technician)

Main Fields of Research

Our objective is to identify and elucidate immunological and molecular mechanisms involved in the pathogenesis of skin diseases as a template for the discovery of novel therapeutic approaches. Our research activities are focussed on the mechanisms leading to innate immune responses in the skin upon exposure to pathogen and/or danger signals. We are particularly interested in the molecular events involved in Interleukin-1beta processing and secretion during the course of inflammatory dermatoses.

Selected References

Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, Rôques S, Friedmann PS, Contassot E, French LE. TNF- α and IFN- γ are Potential Inducers of Fas-Mediated Keratinocyte Apoptosis through Activation of Inducible Nitric Oxide Synthase in Toxic Epidermal Necrolysis. *J Invest Dermatol*. 133: 489, 2013

Jankovic D, Ganesan J, Bscheider M, Stickele N, Weber F, Guarda G, Follo M, Pfeifer D, Tardivel A, Ludigs K, Bouazzaoui A, Kerl K, Fischer J, Haas T, Schmitt-Gräff A, Manoharan A, Müller L, Finke J, Martin S, Gorka O, Peschel C, Ruland J, Idzko M, Duyster J, Holler E, French LE, Poeck H, Contassot E, Zeiser R. The Nlrp3-inflammasome regulates acute graft-versus-host disease. *J Exp Med*, 10: 1899-910, 2013

Bouchaud G, Gehrke S, Krieg C, Kolios A, Hafner J, Navarini AA, French LE, Boyman O. Epidermal IL-15R α acts as an endogenous antagonist of psoriasisiform inflammation in mouse and man. *J Exp Med*, 10: 2105-17, 2013

Kistowska M, Gehrke S, Jankovic D, Kerl K, Fettelschoss A, Feldmeyer L, Fenini G, Kolios A, Navarini A, Ganceviciene R, Schaubert J, Contassot E, French LE. IL- β Drives Inflammatory Responses to Propionibacterium acnes In Vitro and In Vivo. *J Invest Dermatol*, 134: 677-85, 2013

Kistowska M, Meier B, Proust T, Feldmeyer L, Cozzio A, Kuendig T, Contassot E, French LE. Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients. *J Invest Dermatol*, 135: 110-8, 2014





Group Members

Prof. Dr med. Reinhard Dummer (group leader)
 Mirjana Maiwald (-Urosevic), Prof. , group leader lymphoma
 Mitch Levesque, Prof. , group leader melanoma

Simone Goldinger, MD
 Sima Rozati, MD
 Marieke Raaijmakers, MD
 Daniel Widmer, Ph.D
 Phil Cheng, Ph.D student
 Daniel Hug
 Jil Dreier

Study Nurses
 Karen Meyer

Main Fields of Research

We have intensively studied the immune biology of cutaneous lymphomas, cutaneous melanoma and epithelial skin cancers. Based on the microenvironment of these tumors, we have established immune interventions in cell cultures and animal models. Translational research applies this new knowledge to our patients in order to provide effective treatment with best quality of life.

Selected References

Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zübel A, Moutouh-de Parseval L, Dummer R, Goldinger SM. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. *Ann Oncol* 2014; 25: 1437-41

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol*, 2014; 15: 323-32

Robert C, Dummer C, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer St, Middleton MR. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. *Lancet Oncol* 2013; 14: 733-40

Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MI, Hemmi S, Dummer R, Levesque MP. Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1 α -Dependent Phenotype Switching. *Journal Invest Dermatol* 2013; 133: 2436-43



Group Members

Prof. Dr med. Jürg Hafner (Group Leader)
 Dr med. Claude Luder

Main Fields of Research

Oncologic dermatologic surgery
 Dermatology and vascular medicine
 – Wound healing
 – Phlebology and angiology
 – Compression therapy

Founding: JH Rahn Foundation, Zurich (supporting clinical research and post-graduate training in dermatologic surgery, phlebology and wound healing)

Selected References

Löser C, Rempel R, Breuninger H, Möhrle M, Häfner HM, Kunte C, Hassel J, Hohenleutner U, Podda M, Sebastian G, Hafner J, Konz B, Kaufmann R (on behalf of the German Society for Dermatologic Surgery): J Dtsch Dermatol Ges. 2010 Nov;8(11): 920-5

Hafner J, Nobbe S, Partsch H, Läubli S, Mayer D, Amann-Vesti B, Speich R, Schmid C, Burg G, French LE. Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriosclerosis. *Arch Dermatol*. 2010 Sep;146(9): 961-8

Alavi A, Hafner J, Dutz JP, Mayer D, Sibbald RG, Criado PR, Senet P, Callen JP, Phillips TJ, Romanelli M, Kirsner RS. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. *J Am Acad Dermatol*. 2013 Dec;69(6): 1033-1042

Sippel K, Seifert B, Hafner J. Donning devices (foot slips and frames) enable elderly people with severe chronic venous insufficiency to put on compression stockings. *Eur J Vasc Endovasc Surg*. 2015 Feb;49(2): 221-9

Luder C, Dziunycz P, Omid N, Radetzki AL, Lang C, Hübner M, Hafner J. A compression kit of a stocking and superposed leggings is easy to do and dose adjustable. *Eur J Vasc Endovasc Surg*: Submitted

Hafner J, Aschwanden J, Goldinger SM, Dummer R, Mühlstädt M. Behandlung von Satelliten-, In-transit- und Hautmetastasen des Melanoms: Elektrochemotherapie steigert Medikamentenkonzentration *Swiss Medical Forum* 2015; 15: 120-122



Group Members

Prof. Dr. med. Günther FL Hofbauer (group leader)

Paola Atzei, PhD

Sandra Freiburger, PhD student

Johannes Neu, PhD student

Meisam Khorrami, pract. med.

Dr med. Piotr Dziunycz

Dr med. Chantal Bachmann

Dr med. Mosaab T. Mohanna

Elias Burri

Joana do Cabo, med. pract.

Sara Frauenfelder

Luca Funk

Emanuel Lengwiler

Anna Müller

Barbara Ruiys

Larissa Meier, med. pract.

Marina Schneider

Anais Schneider

Nadja Stenz

Daniel Stimpfle, med. pract.

Gilles Straub, med. pract.

Main Fields of Research

Our research activities are focused on squamous cell carcinoma of the skin. We have a special interest in organ transplant recipients as a high-risk population for the development of squamous cell carcinoma of the skin stemming from the combined effects of immunosuppression and ultraviolet light. Our research is thus focused on inflammation fighting skin cancer or contributing to the cutaneous carcinogenesis as well as on the role of UV damage in particular in conjunction with medication.

Selected References

Pain identifies squamous cell carcinoma in organ transplant recipients: the SCOPE-ITSCC PAIN study.

Bouwes Bavinck JN, Harwood CA, Genders RE, Wisgerhof HC, Plasmeijer EI, Mitchell L, Olasz EB, Mosel DD, Pokorney MS, Serra AL, Feldmeyer L, Baumann Conzett K, Piaserico S, Belloni Fortina A, Jahn K, Geusau A, Gerritsen MJ, Seckin D, Gulec AT, Cetkovska P, Ricar J, Imko-Walczuk B, Proby CM, Hofbauer GF. *Am J Transplant.* 2014;14(3): 668-76

The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light. Dziunycz PJ, Lefort K, Wu X, Freiburger SN, Neu J, Djerbi N, Iotzowa-Weiss G, French LE, Dotto GP, Hofbauer GF. *J Invest Dermatol.* 2014;134(7): 1998-2004

Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Hu B, Castillo E, Harewood L, Ostano P, Raymond A, Dummer R, Raffoul W, Hoetzenecker W, Hofbauer GF, Dotto GP. *Cell.* 2012; 149(6): 1207-20.



Group Members

PD Dr Dr Wolfram Hötzenecker (group leader)

Dr med. E. Guenova-Hötzenecker, PhD

Dr med. N. Jaberg-Bentele

Dr med. E. Kretzschmar

Main Fields of Research

Our research activities are mainly focused on the function of the cutaneous immune system in health and disease. Thereby we have a special interest in the pathophysiology of severe cutaneous drug reactions. In that context we aim to identify the phenotype and function of resident immune cells of the skin in cutaneous drug reactions. Furthermore, we are interested in analyses of the impact of cellular stress (ROS) on tumor stroma and tumor formation as part of an ongoing collaboration with Prof. Dotto (Lausanne) and Dr Schatton (Boston).

Selected References

Guenova-Hötzenecker E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kim KW, Park JH, Seo JH, Ignatova D, Cozzio A, Levesque MP, Volz T, Koberle M, Kaesler S, Thomas P, Mailhammer R, Ghoreschi K, Schakel K, Amarov B, Eichner M, Schaller M, Clark RA, Rocken M, Biedermann T. *Proc Natl Acad Sci U S A.* 2015; 112: 2163-8.

Hu B, Castillo E, Harewood L, Ostano P, Raymond A, Dummer R, Raffoul W, Hötzenecker W, Hofbauer GF, Dotto GP: Loss of mesenchymal CSL signaling leads to field cancerization and multifocal epithelial tumors. *Cell.* 2012; 149: 1207-20.

Guenova-Hötzenecker E, Hötzenecker W: Case 1-2012: a man with persistent ulcers on the hands. *N Engl J Med.* 2012; 366:1450.

Hötzenecker W, Echtenacher E, Guenova-Hötzenecker E, Hoetzenecker K, Woelbing F, Brueck J, Teske A, Valtcheva N, Fuchs K, Kneilling M, Park J-H, Kim K-H, Kim K-W, Hoffmann P, Krenn C, Hai T, Ghoreschi K, Biedermann T, Rocken M: ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immune-suppression. *Nat Med.* 2012; 18: 128-34



Group Members

PD Dr med. Thomas Kundig
Head of Research, Dept. of Dermatology
Pal Johansen, PD PhD
Ying Men-Wäckerle, PD PhD
Steve Pascolo, PhD
Martin Bachmann, Prof. Dr, PhD
Gery Jennings, PhD
Antonia Fettelschoss, PhD Postdoc
Franziska Zabel, PhD Postdoc

Associated members (from Clinical Trials Center)

Gabriela Senti, PD MD
Fabian Tay, MD
Christine Tivig, MD
Eva Betschart, Master Science
Lara Spina, Master Science

Main Fields of Research

The major focus of research is the development and testing of new concepts of vaccination and immunotherapy for the treatment of allergies, infections, cancer and inflammatory diseases. Typically, treatment strategies are developed and tested in mice, but several strategies have been transferred to clinics and tested in randomized and controlled clinical phase I / II and currently also phase III trials.

Selected References

Pihlgren M, Silva AB, Madani R, Giriens V, Waeckerle-Men Y, Fettelschoss A, Hickman DT, López-Deber MP, Ndao DM, Vukicevic M, Buccarello AL, Gafner V, Chuard N, Reis P, Piorkowska K, Pfeifer A, Kündig TM, Muhs A, Johansen P. TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. *Blood*, 2013; 121: 85-94

Intralymphatic immunotherapy: time interval between injections is essential. Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. *J Allergy Clin Immunol*, 2014; 133: 930-1



Group Members

Prof. Dr sc. nat. Mitch Levesque (group leader)
Dr sc. nat. Daniel Widmer
Dr sc. nat. Phil Cheng
Dr sc. nat. Ossia Eichhoff
Dr med. Verena Paulitschke
Marieke Raaijmakers
Theodora Chatziisaak
Andreas Dzung
Alice Langer
Melanie Maudrich
Mirka Schmid

Main Field of Research

We are interested in using functional genomics tools to understand the evolution of heterogeneity in skin cancer progression. In particular, we apply next-generation sequencing approaches to melanoma and other skin cancers. With access to one of the largest live-cell melanoma biobanks in the world, we have a unique resource in which to study the functional mechanisms of cellular heterogeneity and how these respond to various therapeutic regimens. Lastly, we are using the zebrafish model organism as a means to functionally validate novel genes from our genomics assays. The zebrafish is an emerging model organism that offers many advantages over traditional models according to the 3Rs (Replacement, Reduction, Refinement), and allows for a rapid functional assessment of the human cancer genome.

Selected References

<https://scholar.google.ch/citations?user=kC5QI6sAAAAJ&hl=en>

Cheng, PF, Shakhova, O, Widmer, DS, Zing, D, Benedetta, B, Raaijmakers, MMI, Eichhoff, OM, Goldinger, SM, Hemmi, S, Hoek, KS, Sommer, L, Dummer, R, Levesque, MP. (2015). Methylation dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. *Genome Biology* 16: (1)42

Widmer, DS, Hoek, KS, Cheng, PF, Eichhoff, OM, Biedermann, T, Raaijmakers, MIG, Hemmi, S, Dummer, R, and Levesque, MP. (2013). Hypoxia contributes to melanoma heterogeneity by triggering HIF1 α -dependent phenotype switching. *Journal of Investigative Dermatology* (March 8. doi: 10.1038/jid.2013.115)

Das Thakur, M, Salangsang, F, Landman, AS, Sellers, WR, Pryer, NK, Levesque, MP, Dummer, R, McMahon, M, and Stuart, D. (2013). Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. *Nature* doi:10.1038/nature11814

Funding Sources

Verein für Hautkrebsforschung, Swiss National Science Foundation, Krebsliga Schweiz, Horizon 2020



Group Members

Prof. Dr med. Mirjana Maiwald (-Urosecvic)
Associate professor (Titularprofessorin)
Attending physician

Main Field of Research, Abstract

Cutaneous lymphomas are a heterogeneous group of extranodal lymphomas that are characterized by primary skin involvement. Recent discoveries of changes in molecular biology and immunology of these tumors have provided better understanding of the processes that govern lymphoma development in the skin. I investigated different biologic and immunologic aspects of cutaneous T- and B-cell lymphomas that may help develop more efficient and targeted therapeutic approaches. Despite a myriad of molecules that can be delivered by gene transfer, only cytokine gene transfer has entered clinical development in the field of primary cutaneous T- and B-cell lymphomas, where we are also involved. Furthermore, I am interested in dissecting immune pathways that are involved in tumor regression during different types of immunotherapy as well as other targeted therapies not only in cutaneous lymphomas but also in other skin cancers. As a counterpart of immune response stimulators, I am also keen to elucidate mechanisms governing immune system evasion by the tumor cells.

Main Fields of Research, Keywords

Cutaneous lymphoma
Gene therapy of skin cancer
Immunotherapy of skin cancer
Gene expression profiling of immune responses in skin cancer
Immune evasion mechanisms in skin cancer

Selected References

Dreno B, Urosecvic-Maiwald M, Kim Y, Guitart J, Duvic M, Dereure O, Khammari A, Knol AC, Derbij A, Lusky M, Didillon I, Santoni A-M, Acres B, Bataille V, Chenard M-P, Bleuzen P, Limacher J-M, Dummer R (2014). TG1042 (adenovirus-interferon- γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial. *PLoS One*. 24;9(2): e83670

Accart N, Urosecvic-Maiwald M, Dummer R, Bataille V, Kehrer N, Nicolescu C, Limacher JM, Chenard MP, Bonnefoy JY, Rooke R (2013). Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042. *J Transl Med* 11: 226-237

Walter A, Schäfer M, Matter C, Urosecvic-Maiwald M, Belloni B, Schönewolf N, Cecconi V, Kulig P, Knuth A, Dummer R, Bloch W, Werner S, Beer H-D, Van den Broek M (2013). Aldara activates imiquimod-independent immune defense. *Nat. Commun* 4:1560. doi: 10.1038/ncomms2566

List of Publications in Pubmed

<http://www.ncbi.nlm.nih.gov/pubmed?term=urosecvic%20m%20AND%20zurich%20OR%20urosecvic-maiwald%20m>



Group Members

PD Dr sc.nat Alexander Navarini (group leader)

MSc Rebecca Higgins
Dr med. Antonios Kolios
Dr med. Tatjana Maul

Main Fields of Research

Our group investigates disease-driving genetic mutations in inflammatory skin conditions. We are investigating linear localized scleroderma, severe acne, paradoxical psoriasis-like reactions to TNF alpha inhibitors, pyoderma gangrenosum and other conditions. Recently, we demonstrated the genetics of severe acne and identified potential new treatment targets.

Selected References

Kolios AGA, French LE, Navarini AA. Detection of small changes in psoriasis intensity with the PrecisePASI. *Dermatology*, 2015; 230: 314-7

Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C (2014). Homozygous Missense Mutation in IL36RN in Generalized Pustular Dermatitis With Intraoral Involvement Compatible With Both AGEP and Generalized Pustular Psoriasis. *JAMA Dermatol*, 2015; 151: 452-3

Navarini AA*, Simpson MA*, Weale M*, Knight J, Carlavan I, Reiniche P, Burden DA, Layton A, Bataille V, Allen M, Pleass R, Pink A, Creamer D, English J, Munn S, Walton S, Willis C, Acne Genetic Study Group, Deret S, Voegel J, Spector TD, Smith CH, Trembath RC, Barker JN (2014). Genome-wide association study identifies three novel susceptibility loci for severe acne vulgaris. *Nature Communications* Jun 13; 5: 4020

Navarini AA*, Valeyrie-Allanore L*, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, Roujeau JC, Sekula P, Simpson MA, Trembath RC, Mockenhaupt M, Smith CH (2013) Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis. *J Invest Dermatol*, 2013; 133: 1904-7



Group Members

Prof. Dr med. Peter Schmid-Grendelmeier (group leader)

Dr med. Meike Distler
Dr med. Matthias Drach
Dr med. Antonios Kolios
Dr med. Tatjana Maul
Dr med. Kirsten Schiesser
Dr med. Christina Weber
Selin Stäger
Suzanne Marti Wyss
Muriel Träxler

Main Fields of Research

Our research activities are focused on epidemiology, pathophysiology and treatment of allergic diseases, namely atopic dermatitis.

We also investigate new regimens and therapeutic options in a variety of diseases, from pollen allergy to rarer ones such as mastocytosis and hereditary angioedema.

Recently we have also started to implement, evaluate and improve educational tools to promote knowledge and training in allergic diseases.

Selected References

Brodská P, Panzner P, Pizinger K, Schmid-Grendelmeier P.
IgE-mediated sensitization to malassezia in atopic dermatitis: more common in male patients and in head and neck type.
Dermatitis. 2013; 25(3): 120-6

Gassner M, Gehrig R, Schmid-Grendelmeier P.
Hay fever as a Christmas gift.
N Engl J Med. 2013 24; 368(4): 393-4

7. University Research Priority Program (URPP) Translational Oncology

Since 2012 the Department of Dermatology plays a significant role within the URPP = University Research Priority program. The University Zurich has committed for this program a budget of CHF 6 mill. over a period of 4 years in order to follow designated research projects. This URPP is directed by Prof. Dr Lars French, along with vice-director Prof. Conrad Basler and the scientific coordinator Prof. Dr Maries van den Broek.

Thanks to significant developments in research, prevention and therapy, age-adjusted cancer death rates are finally decreasing for certain types of cancer including lung, colon, prostate, breast and uterus. Despite this encouraging development, too many people still suffer from the major effects of being diagnosed with cancer, from an important reduction in the quality of life and often still from a reduced life expectancy. Both the University and the University Hospital of Zurich have inscribed cancer research and oncology – the branch of medicine that deals with cancer – amongst its top priorities. The funding of our URPP Translational Cancer Research clearly underscores the commitment of our University to promoting innovative cancer research and translation of the latter to the clinic through high quality science. The URPP Translational Cancer Research is unique and original in that it unites an exceptional team of internationally recognized scientists and physician-scientists in the field of oncology and cancer research, and is determined to bridge the unfortunate gap in communication and collaboration between physicians and basic scientists to bring cancer research a step closer to translation into the clinic.


The research in the URPP Translational Cancer Research specifically focuses on the following four subprojects:

1. Oncogenic signal transduction pathways as targets for personalized tumor therapy
2. The interaction between cancer and the immune system
3. Tumor biopsy and live tumor cell biobank linked with clinical outcome data
4. Translation from bench to bedside

Additional information concerning the URPP Translational Cancer Research can be found on: www.cancer.uzh.ch



The directors of the URPP Translational Cancer Research. Professors French, Basler and van de Broek from left to right.



8. New Clinician-Scientists and Scientists



FNS-NF
SCHWEIZERISCHER NATIONALFONDS
ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG

Dr med. Emmanuella Guenova-Hötzenecker

In 2013, Dr med. Emmanuella Guenova-Hötzenecker, PhD joined the University of Zurich and the Department of Dermatology as a recipient of the prestigious Marie Heim-Vögtlin Career Development Grant of the Swiss National Science Foundation. Dr Guenova-Hötzenecker graduated summa cum laude from the English Language School in Sofia, Bulgaria, and completed her medical school training mainly in Bulgaria and Germany. For her studies on the regulatory role of cytokines in cutaneous autoimmune diseases, Dr Guenova-Hötzenecker was awarded an MD and a PhD degree from the Eberhard Karls Universität, Tübingen, Germany and from the Medical University Sofia, Bulgaria. After receiving her board certification in dermatology, allergology and cutaneous oncology in Germany, Dr Guenova-Hötzenecker pursued cutaneous T cell lymphoma as her main interest in basic and clinical research and joined the Brigham and Women's Hospital and the Harvard Medical School as a postdoctoral fellow and subsequently as a recipient of a Career Development Grant of the German Research Foundation. In the laboratories of the Harvard Skin Disease Research Center, led by Tom Kupper and Rachael Clark, Dr Guenova-Hötzenecker closely studied mycosis fungoides and Sèzary syndrome, two common cutaneous T cell lymphomas. She discovered that malignant T cells are prone to express a distinct T cell phenotype, which could result in immune suppression and impaired pathogen defence in tumour patients.

In Zurich, Dr Guenova-Hötzenecker remains committed to high level translational research, with a clinical and research focus on immune regulatory mechanisms in skin diseases, cutaneous lymphoma and dermatopathology.



PD Dr med. Wolfram Hötzenecker

After completion of medical school at the University of Vienna 2001, I was involved as a PhD student in the working group of Prof. Elbe-Bürger at the Department Of Dermatology, Medical University Of Vienna for three years. During my doctorate I investigated the modulating effect of new topical immunosuppressants on the autochthonous immune system of the skin. Following the completion of my PhD degree I moved to the Department of Dermatology, Tübingen University Hospital, Germany, where I continued with research on oxidative stress and the immune system beside my clinical work. After completion of my specialist training, I joined the Harvard Medical School, Boston as a Research Fellow in Dermatology where, based on the results obtained in Tübingen, I studied the effects of ATF3 on skin tumors in greater detail. In 2013 I finally joined the University Hospital Zurich (UHZ), Division of Dermatology, where I am currently completing my second residency in Allergology & Clinical Immunology. My main focus of research is the pathogenesis of cutaneous drug reactions and drug allergy.



PD Dr med. & Dr sc. nat. Alexander Navarini

PD Dr med. Dr sc. nat. Alexander Navarini studied medicine in Basel and Paris and subsequently investigated neutrophil immune reactions and delayed-type adaptive immune responses in the laboratory of Professors Zinkernagel and Hengartner. His internships included internal medicine at Bruderholzspital Basel, infectious and tropical diseases at the Swiss Tropical Institute (Tanzania), and Dermatology and Venereology at the Department of Dermatology at the University Hospital Zurich, where he specialized in immunologic therapies with Biologics. He passed FMH and the European (UEMS/EBDV) board exams for dermatology and venereology in 2010. During a senior research fellowship at King's College in London 2012-14, he reported the genetic architecture of severe acne as well as causal mutations for several pustular dermatoses including AGEP, palmoplantar pustulosis and acrodermatitis continua suppurativa Hallopeau. His clinical priority fields of expertise as attending physician is psoriasis, acne, hidradenitis suppurativa and eczema, and current research projects investigate severe acne, eczema, pyoderma gangrenosum and paediatric linear localized scleroderma.

Dr med. Martin Glatz

Previous positions

Moving from Graz to Zurich in 2009, I have finished my training in dermatology at the Department of Dermatology at the University Hospital in Zurich in 2012. From 2012 until 2014 I was a postdoctoral fellow at the Dermatology Branch at the National Institutes of Health (NIH) in Bethesda, MD, USA. Funded by the Swiss National Science Foundation and a research award from the intramural research program at the NIH, I investigated the influence of skin microbial communities on the development and course of atopic dermatitis.

Current position

By beginning of 2015 I have returned to Zurich and I am currently in training for the board certification for allergy and clinical immunology at the Allergy Unit at the Department of Dermatology as well as the Department of Immunology at the University Hospital of Zurich. The position at the Allergy Unit is funded by the CK Care Foundation.

Current function

My current function comprises patient care at both departments and research on atopic dermatitis. In particular, I am interested on the influence of the yeast *Malassezia* spp. on the course of this disorder. This research is supported by a research grant of the Deutsche Stiftung Dermatologie and the Arbeitsgemeinschaft Dermatologische Forschung.



Prof. Mitch Levesque, PhD

Professor Levesque received his PhD from Duke University in the United States in 2005 where he developed new computational tools to analyze large datasets. These included novel techniques to compare whole genome sequences as well as algorithms to reduce dimensionality in complex gene expression data. As a post-doctoral researcher in the lab of Nobel Laureate Prof. Christiane Nüsslein-Volhard at the Max Planck Institute, Professor Levesque applied some of these computational techniques to developmental pathways in the Zebrafish model organism. The main focus of his research in Zürich is to continue to generate new computational approaches to reducing large datasets relevant to translational cancer research, and to use Zebrafish to more quickly test the function of novel genes in an in vivo context.




Figure 1: Schematic of the evolution of melanoma heterogeneity (Widmer, Eichhoff, Dummer and Levesque 2015)

9. Clinical research: The Zurich University Hospital Dermatology Clinical Trial Unit

Clinical research is a major focus in an academic center like ours. It is essential to translate new basic research results into beneficial treatment regimens. Clinical trials today are performed in an increasingly regulated network uniting clinical, ethical, legal and economic aspects. Absolutely central to this is the respect of involved patients life, well-being, and integrity of all personnel involved (principles of good clinical practice).

In order to achieve this, a network of clinical trial specialists is necessary so that clinical trials can be integrated in the treatment strategy for the respective diseases.

The department of dermatology and the skin cancer unit have a long and successful record in this context. We are and have been a major research center for the development of targeted therapy and immunotherapy for skin cancers and immune-mediated skin diseases. The clinical trial unit of our center has extensive experience in early and late phases of clinical development (phase I-IV).

There are of a number of phase I studies including first-in human with gene-therapy approaches such as adeno-interferon-gamma (TG 1064) that further increased our broad expertise in clinical trials. In addition, we have even performed a highly complicated phase I trial in cooperation with our in-house department of nuclear medicine that allowed monitoring drug excretion after application of a radioactive dose of study drug (mass balance analysis).

In recent years, the clinical trial unit has worked with many molecules including:

- 3 BRAF-inhibitors
- 4 MEK-inhibitors
- 2 Anti-CTLA-4 antibodies
- 2 Anti-PD1 antibodies
- MDM2 inhibitors

- Somatostatin-analogons
- Antisense-BCL-2 Nucleotides
- Tyrosine kinase inhibitors including nilotinib, pazopanib, lapatinib and sorafenib
- Gene therapy including Allovectin-7 and adeno-interferon gamma and canary pox viral vectors
- Pan-kinase and Anti-VEGF inhibitors
- Monoclonal antibody-cytokine fusion proteins
- Vaccines
- Antimicrobial agents (taurolidine)
- PEG interferon
- Various Chemotherapies
- Hedgehog Pathway Inhibitors
- Histone-Deacetylase Inhibitors (HDAC)
- RXR Retinoids
- NAD+ biosynthesis inhibitors
- Purine Nucleosid Phosphorylase inhibitors
- Resiquimod
- IL-17A and IL-17R antibodies
- PDE4 inhibitors
- TNF- α antagonists
- IL-12/23 antibodies
- IL-1 β antagonists
- IL1Ra soluble receptor
- Topical parathormone
- Topical Vitamin D3 analogons
- Anti-IgE antibodies

In the field of investigator initiated trials we have focused mode on of action studies. We were able to monitor the impact of multi kinase inhibitors in vivo by transcriptional analyses (large scale).

In addition, we focus on the development of different investigator initiated trials (IITs) for the treatment of orphan diseases of the skin or for subgroups of skin cancer patients with high medical need.

Although limitations in space and resources in the face of increasing innovative trials and regulations currently limit further expansion, our clinical trial unit is today one of the leading clinical research centers in Europe.

Head of Clinical Research Dermatology: Prof. Dr med. R. Dummer, Vice-Chairman

Inflammatory Skin Disease

Prof. Dr P. Schmid, Leitender Arzt

Dr med. W. Hötzenecker, Oberarzt

Prof. Dr L. E. French, Klinikdirektor

Dr med. L. Imhof, Oberärztin
PD Dr med. A. Navarini, Oberarzt

Dr med. T. Maul, Assistenzärztin
Dr med. M. Distler, Assistenzärztin

Dr med. T. Maul, Assistenzärztin
Dr med. A. Kolios, Assistenzarzt

Cutaneous Oncology

Prof. Dr R. Dummer, Stv. Klinikdirektor

Prof. Dr G. Hofbauer, Leitender Arzt

Dr med. S. M. Goldinger, Oberärztin

Dr med. A. Frauchiger, Assistenzärztin
Dr med. A. Micaletto, Assistenzärztin
Dr med. M. Kunz, Assistenzarzt

Dr med. C. Bachmann, Assistenzärztin

10. Research Foundations

Our department has two charitable foundations aimed at ultimately improving patient care by providing support for high quality research on the mechanisms of skin disease. The activities of the foundations are made possible by generous donations from patients and the public as well as industry.

Bruno Bloch-Stiftung

- The Bruno Bloch Foundation [www.brunoblochstiftung.ch] was founded in 1935 by the widow of Prof. Bruno Bloch, Chairman of the Zurich Dermatology Department between 1916 and 1933; this foundation supports skin research and education activities specifically at the department of dermatology of the university of Zurich, including research on severe skin diseases such as inflammatory skin disease and skin cancer.
- One of the traditions and highlights of the Bruno Bloch Foundation are the yearly Memorial Lectures which take place in February with over 200 Faculty Members and Students at the Zurich University Hospital. In 2014, the Bruno-Bloch Memorial Lecture was held by Professor Martin Röcken, Chairman in Dermatology of the Tübingen University, Germany. The lecture was devoted to psoriasis.

Charity Concert by Anne-Sophie Mutter

- For the first time in 2013 the Bruno Bloch Foundation organized a Charity concert by with the exceptional contribution of Anne-Sophie Mutter. The collected funds served to finance the research for skin diseases and skin cancer of the Department of Dermatology at the Zurich University Hospital. Important donators supported this charity evening and made it possible to generate a substantial benefit in favor of the research. Given this success the Bruno Bloch Foundation will organize its second Charity evening in November 2015. For more information: www.brunoblochstiftung.ch



Memorial Lecture 2014: Guest speaker
Prof. Dr Martin Röcken & Prof. Dr Lars French



Charity Recital for the Bruno Bloch Foundation with
Anne-Sophie Mutter & Lambert Orkis, Tonhalle Zurich

Bruno Bloch-Stiftung für eine gesunde Haut



Gedächtnisvorlesungen:

Prof. U. Schnyder, 1991

Prof. E. Schöpf, 1992

Prof. O. Braun-Falco, 1993

Prof. E. Frenk, 1995

Prof. Th. Ruffli, 1996

Prof. D. Petzoldt, 1997

Prof. R. Panizzon, 1998

Prof. H. Wolff, 1999

Prof. St. Büchner, 2000

Prof. H. Kerl, 2001

Prof. L.R. Braathen, 2002

Dr. G. Albrecht, 2003

Prof. D. Hohl, 2004

Prof. P. Elsner, 2005

Prof. R. Kaufmann, 2006

Prof. N. Yawalkar, 2007

Prof. M. Hertl, 2008

Prof. P. Itin, 2009

Prof. Th. Schwarz, 2010

Prof. A. Enk, 2011

Prof. M. Gilliet, 2012

Prof. T. Ruzicka, 2013

Prof. M. Röcken, 2014

Prof. A. Bircher, 2015

Konzert

Benefiz-Gala mit Anne-Sophie Mutter

Zürich, Tonhalle - Die Geigerin Anne-Sophie Mutter ist ja keine, die sich gern in die Werkstatt schauen liesse. Was sie auf dem Podium präsentiert, ist technisch wie musikalisch ausgefeilt und durchinszeniert bis hin zur Wahl des schulterfreien Kleides, das diesmal so gelb war wie das Logo der Deutschen Grammophon, die ihre CDs herausgibt. Umso erstaunlicher war der Beginn ihrer Benefiz-Gala für die mit der Bekämpfung von Hautkrankheiten befassten Stiftung Bruno Bloch: Da stimmte ihr Stammpianist Lambert Orkis gewohnt geschmeidig Mozarts Sonate KV 379 an - bis die Geigerin mit derart schattigem Ton einfiel, dass er sofort ins Pianissimo zurückschalten musste. Auch im zweiten Satz war seine Reaktion gefragt, denn Anne-Sophie Mutter trieb das Tempo an, als ob sie jede Pause für verschwendete Zeit hielt.

Man hörte und staunte und freute sich. Denn das klang nun gar nicht nach jener Luxus-Konfektionsware, die Mutter im klassischen Repertoire so oft serviert. Diesmal ging sie für die Sätze von Mozart, Grieg, Debussy und Franck Risiken ein, wie sie das sonst nur bei zeitgenössischem tut. Immer wieder liess sie ihren Klang vibratolos und fahl werden (saalfüllend blieb er trotzdem). Wo andere Violinistinnen ihr Ausdrucksspektrum ins Schrofne erweitern, suchte sie den leisen, fragilen, sozusagen rezitativen Ton. Und in den langsamen Sätzen schien sie sich aus dem Saal hinauszuträumen, in eine Klangsphäre, in der das Wohlvertraute wieder zart und kostbar ist.


Denn klar, kostbar war auch in diesem Konzert alles, was Anne-Sophie Mutter bot. Die Zerbrechlichkeit war gewollt und kontrolliert. Und niemand brauchte überrascht zu sein, als sie es bei der Zugabe mit Brahms' «Ungarischem Tanz Nr. 1» doch noch so richtig knallen liess. Nur Lambert Orkis musste sich noch einmal sputen, damit er alle ihre Tempowechsel mit- und hinbekam.

Susanne Kübler

*Aktuelle CD mit Anne-Sophie Mutter:
Werke von Dvorák mit den Berliner
Philharmonikern; Ltg. Manfred Honeck
(Deutsche Grammophon).*

Association for Research on Cancer of the Skin (Verein für Hautkrebsforschung)

- The Association for Research on Cancer of the Skin, [www.skincancer.ch] – founded in 2004 – aims to coordinate and stimulate skin cancer research in Switzerland by supporting research in rare and severe forms of skin cancer (e.g. melanoma, cutaneous lymphoma). The board consists of Prof. Dr R. Dummer, Zurich, Prof. Dr L. French, Zurich, Prof. Dr D. Hohl, Lausanne, Prof. Dr R. Hunger, Berne, Prof. Dr R. Kaufmann, Frankfurt, and Prof. Dr W. Kempf, Zurich; it is currently chaired by Prof. R. Dummer. The current goal is to generate a substantial contribution to clinical and experimental skin cancer research in the department in Zurich and in other institutions in Switzerland.
- Recently, the association has created an assistant professor position at The University of Zurich. Prof. Dr Mitch Levesque, an internationally renowned melanoma researcher, will hold the position for at least 4 years starting from February 1st, 2014. His research activities involve developing new tools for understanding next generation sequencing data, and functionally testing novel melanoma mutations in the lab. In this context he is using the zebrafish model organism to better understand the basic biology of cancer genes. In his new function Prof. Levesque also manages the Dermatooncology biobank at the USZ, which provides a diverse collection of live cancer cells to collaborators for experimental research. These are fundamental research activities that are the basis for understanding melanoma progression and for future improvements in melanoma therapy.
- “The picture shows a section of a skin biopsy from a basal cell carcinoma patient after hedgehog inhibitor treatment. Immunohistochemical staining reveals a post-therapy increase of peri- and intratumor CD4+ T cells in the tumor area.” By Levesque M, Clin Cancer Res March 15, 2015 21; 1289



11. Medical Education / Teaching

Medical education is crucial to guarantee a high level of professionalism of physicians and health care professionals. Our continued implication in education is reflected by

1. Education of students in the medical faculty of the university
2. Specialized training in Dermatology of resident physicians for board-certification in “Dermatology”, and in “Allergology and Immunology” for residents board certifying in allergology and clinical immunology
3. Continuing medical education of private practitioners – mainly dermatologists and allergologists, but also general practitioners and to a lesser extent other health care professions.

Education for students: Senior physicians of our department provide an introductory course for dermatology to 3rd year medical students, a yearly core course in dermatology (8-day Themenblock) to 4th year medical students, a new case-based thematic lecture series in the 6th year, and a practical training course in dermatology in the 6th year of the medical training curriculum at the University of Zurich. In complement to these ex-cathedra and bed-side teaching activities, medical students can benefit from web-based learning using an online platform (DOIT: Dermatology Online with Interactive Technology) developed by our Department under the direction of former Chairman (Prof. Dr med. Dr h. c. Günter Burg) in a close collaboration with several other dermatology departments (Basel, Bern, Lausanne, Jena and Stadtspital Triemli in Zurich and the European Dermatology Forum).

This platform is being continuously improved and currently exists in six languages and two further languages are scheduled. In 2009 the DOIT Platform was elected as the best internet based teaching platform and distinguished with the 50,000 Euro Medida Prize.

Resident physicians

The Department of Dermatology offers 22 residency positions for the 5 years of obligatory training required for obtaining swiss board certification in dermatology. Demand for residency training in our department is extremely high, with more than 150 applications for approximately 4 available positions per year. 2 training positions are also available for part of the board certification in immunology and allergology, as well as that of angiology. During their residency training in our department, residents benefit of the broadest offer in Switzerland, comprised of a rotation plan through 20 units and specialized clinics covering all

subspecialties of dermatology and allergology, including dermatooncology, autoimmune skin disease, trichology (hair disease), dermatosurgery, dermatopathology, physical skin therapy (radiotherapy, UV-therapy, laser), phlebology and others. Following interest from the German, Austrian and Swiss dermatological societies, the online platform for students (DOIT) is now being used as the base for the development of a paneuropean post-graduate online continuing medical education (CME) platform to be named DERMOKRATES. Our Department and Faculty are actively participating in this innovative project.

Continuing medical education (CME) / Postgraduate training for private practitioners

Our Department and Faculty offer 12–14 CME events and grand rounds per year, comprised in detail of – 6 half-day thematic CME events per year in the University Zurich Irchel (180 – 200 participants), and 6–8 grand rounds and interdisciplinary CME sessions, the latter co-organized with other medical disciplines at USZ. In addition to this, and as of 2007, 4 new CME's per year entitled “Dermatology Update” have been added to our postgraduate teaching program, with the aim of providing a further platform for case presentations, short updates and an overview of important new publications in dermatology (Journal Club).

In addition, in the context of the new “Schwerpunkt Entzündliche Hautkrankheiten”, founded in 2013, our Department organized in 2013 and 2014 four workshops on psoriasis for private practitioners (speakers: Prof. Dr Lars French, Dr Antonio Kolios and Dr Julia-Tatjana Maul). In order to promote the support of the Medical Practitioner Assistances (MPA) four workshops took place under the lead of Dr Antonio Kolios and Dr Julia-Tatjana Maul. The aim of the latter workshops is optimize the support of the MPA of their practitioners themselves by preparing e.g. the PASI-score for the patients in advance to a consultation with the practitioner.

An interesting and interactive exchange motivates us to continue this concept of medical education at a broader range.

Zürcher Dermatologische Fortbildungstage

The “Zürcher Dermatologische Fortbildungstage” were launched in 2011 and immediately proved to be very successful as reflected by the feed-back and the number of participants – mainly practicing dermatologists – which are regularly over 200. The four day intensive continuing medical education event offers a mixture of plenary “state of the art” lectures, hand-on workshops at the Department of Dermatology, and a half-day “What’s new” session. The latter provides the participants an overview of the most important developments in the preceding year. In 2014, the “Zürcher Dermatologische Fortbildungstage” took place in the Zurich Convention Center from June 25 – 28, 2014.

Overview 2013 and 2014

Continuing medical education 2013

Subject / Title	Type of education	Date	Organisation
In Memoriam Prof. Urs W. Schnyder	Dermatology	March 21, 2013	PD Dr A. Cozzio, Prof. L. French
Reihe Regionale Dermatologie: Dermatosen am Kopf	Dermatology	April 11, 2013	PD Dr A. Cozzio
Interdisziplinäre Versorgung von Hautkrebspatienten: Von der Chirurgie zur medikamentösen Therapie	Interdisciplinary	May 16, 2013	Prof. R. Dummer
3. Zürcher Dermatologische Fortbildungstage: Entzündliche Dermatosen	Dermatology	June 12-15, 2013	Prof. L. French, Prof. R. Dummer
Geburtstags-Symposium Prof. Dr Brunello Wüthrich: Ein Leben für Allergiker	Allergology	September 26, 2013	Prof. P. Schmid-Grendelmeier, Prof. B. Ballmer-Weber
Dermatochirurgie LIVE	Dermatology	December 5, 2013	Prof. J. Hafner, Dr S. Läuchli

Continuing medical education 2014

Subject / Title	Type of education	Date	Organisation
20 Jahre Extrakorporale Photopherese am USZ	Dermatology	January 16, 2014	Prof. G. Hofbauer
23. Bruno Bloch-Gedächtnisvorlesung: Psoriasis	Dermatology	February 24, 2014	Prof. L. French
News and Views: Entwicklungen in der Dermatologie	Dermatology	April 10, 2014	PD Dr A. Cozzio
Interdisziplinäre Versorgung von Hautkrebspatienten: Hautkrebstherapie: Neue Medikamente für den Kliniker	Interdisciplinary	May 15, 2014	Prof. R. Dummer
4. Zürcher Dermatologische Fortbildungstage: Regionale Dermatosen	Dermatology	June 25-28, 2014	Prof. L. French, Prof. R. Dummer
7. Internationaler Dermatoskopie Kurs	Dermatology	September 29, 2014	Prof. R. Braun
Dermatochirurgie LIVE	Dermatology	October 30, 2014	Prof. J. Hafner / Dr S. Läuchli



Zürcher Dermatologische Fortbildungstage 2014;
Dr S. Goldinger, Session “What’s New in Dermatoonology”

12. Museum of Wax Moulages



The Museum of Wax Moulages celebrated its 20th anniversary in 2013 with the opening of the new exhibition "Bodies in wax or pixel?"

In 1993 it was the first modern museum that focused on historical three dimensional wax replicas of skin and surgical diseases. In the meantime the Museum became an internationally leading institution concerning the presentation of wax moulages for the public, the use of the historical objects for research in medical history, and the use of the uniquely realistic models for teaching Dermatology at the University.

A professional preservation of the 2000 wax moulages must be the fundament for working with these fragile documents of historical patients. In 2013 a two years project in collaboration with the Bern University of the Arts (BUA) and the Swiss Institute for Art Research in Zurich resulted in the publication of detailed guidelines for the conservation and restoration of wax moulages in general and with special focus on Zurich. On the basis of this work a new depot for the collection was provided by the University Hospital permitting an exemplary storage of the collection. Sabina Carraro as restorer and Michael Geiges as curator advise several institutions with collections of wax moulages in Switzerland and abroad.



One focus for the future will be the completion of the teaching collection with new moulages. Concerning the historical moulages there is a conflict of preserving the fragile objects and the risk of damage when showing them to the public in the museum as well as in other exhibitions as loan collection. Therefore, as a next step, our interest also focuses on duplicating wax moulages without touching them. After first experiments in collaboration with Inspire (Swiss Federal Institute of Technology Zurich) in 2013, we started a new research project in collaboration with the BUA in 2014 on 3D-Scanning and 3D-Printing of wax moulages.

The new exhibition in the Museum demonstrates our three main fields of interest:

- teaching: with the teaching collection referring consistently to the Swiss Catalogue of Learning Objectives for the Medical Training
- history of dermatology and medicine: with moulages documenting medical research, progress and dead ends, and moving stories about patients that have been treated in the first half of the 20th Century at the Dermatology and the Surgery Clinic in Zurich.
- the object itself: with an illustrated history of the use of the medical moulage in academic teaching, the damage symptoms that occur over time with the need for professional conservation and restoration and the idea of producing touch free duplicates.



The Museum of Wax Moulages was Cofounder of the internationally active Working Group for Wax Moulages in Berlin in 2013 and helps building up an international network of Institutions and persons that are in concern of wax moulages. The Museum of Wax Moulages is also engaged in collaboration with the museum of the University of Zurich and was in 2013 Cofounder of the Coordination Group for Museums of the University. The Museum is a member of the Swiss and International Council of Museums and participates actively in the museum scene of Zurich. The museum is well frequented by a broad public and offers guided tours. About half of the visitors have a medical background or visit the museum as part of their formation (e.g. care, cosmetics). An important highlight was again the traditional "Lange Nacht der Museen" when the museum opens its doors until 2 am in the morning with up to 600 visitors in September 2014.



For information about opening times of Museum of Wax Moulages of the University Hospital and the University of Zurich please consult: www.moulagen.ch

Michael L. Geiges, Curator

13. Honors and Prizes

Special Honors

Promotions

Klinikdirektor (Chairman)

Prof. Dr med. Onur Boyman has been elected to be the chairman of the “Klinik für Immunologie USZ” as per February 1st, 2014.

Titularprofessur

PD Dr med. Günther Hofbauer and PD Dr med. Mirjana Maiwald were promoted to the rank of “Titular Professor”.

Assistant professorship

Prof. Dr Mitchell Levesque was awarded an assistant professorship for six years; his position is financed by the Verein für Hautkrebsforschung. He is working in close collaboration with the research group of Prof. Dr med. Reinhard Dummer.

Venia Legendi

- PD Dr Hans-Dietmar Beer
- PD Dr med. Wolfram Hötzenecker
- PD Dr med. Jivko Kamarachev (mainly dermatopathology)
- PD Dr med. Katrin Kerl (mainly dermatopathology)

Oberärzte

- Dr med. Marjam Barysch (Oberärztin i.V.)
- Dr med. Simone Goldinger (mainly dermatooncology) (in addition: Dr S. Goldinger has graduated to the “Facharztstitel of “Pharmazeutische Medizin”)

Prizes

- Prof. Dr med. Onur Boyman received the Gold Award 2013 of the LEO Pharma Research Foundation in the field of treatment of psoriasis, autoimmune and inflammatory diseases and cancer
- Prof. Dr med. Ralph Braun received together with Dr Philippe Held the “Axa Innovation-Prize 2012” for the project “DermoSafe”

- Dr med. Simone Goldinger received the Pierre Fabre Skin Cancer Award 2013 that has been awarded for the first time by the “Verein für Hautkrebsforschung” for the treatment of melanoma patients with metastasis of the brain
- PD Dr med. Wolfram Hötzenecker received the Louis-Widmer Fonds Prize 2013 (SGDV Annual Meeting, Basle 2014)
- Prof. Dr med. Mirjana Maiwald received the Götz-Preis 2013 for her contribution to skin cancer research in the field of cutaneous lymphoma

Named Lectures

Prof. Dr med. Lars French: René Touraine Lecture, International Investigative Dermatology Meeting, Edinburgh, Scotland, 2013

Further promotions

Prof. Dr O. Boyman who was an outstanding Swiss national Science Foundation awardee at our institution was nominated as Professor and Chairman of the Department of Clinical Immunology of the Zurich University Hospital as of 2014.

Prof. Dr med. Peter Schmid-Grendelmeier was elected per July 1st, 2014 as Director of Education of the Christiane-Kühne Center for Allergy Research and Education (CK-CARE).

Research Advancement (Forschungsförderung)

- Dr med. Simone Goldinger received a research grant “Filling the Gap”, a research advancement program funded by the University of Zurich until end of 2015
- Dr med. Emmanuella Guenova-Hötzenecker received by the SNF a highly competitive career advancement of the Marie Heim-Vögtlin foundation for research in tumor immunology and cutaneous lymphoma
- PD Dr med. Wolfram Hötzenecker received advancement funds of the innovation pool of the University Hospital of Zurich for the establishment of lymphocyte transformation tests at the department of allergy in our clinic

14. Partners / Sponsors / Collaboration with Industry and Fund Raising

Our continuous efforts in medical education, public relations, marketing, and networking with private practitioners is only possible thanks to external funding. We collaborate with industry for our postgraduate education, giving private practitioners and industry a platform for communication and exchange. Furthermore possibilities are provided by our charitable foundations the Bruno Bloch Stiftung and the Verein für Hautkrebsforschung. We would here like to acknowledge with great respect the support of our industrial partners. Their collaboration supports the quality and nature of our postgraduate teaching offer. The Department of Dermatology USZ is grateful to the following sponsors and donors for their constant precious and generous support.

With special acknowledgement to our partners of “Schwerpunkt Hautkrebs”

Avène/Pierre Fabre
Cosmétique Active, Schweiz AG
(La Roche-Posay, Laboratoires Vichy)
Galderma SA
Roche Pharma (Schweiz) AG

“Schwerpunkt Entzündliche Hautkrankheiten”

AbbVie AG
Amgen Switzerland AG
Celgene GmbH
Janssen-Cilag AG
Merck Sharp & Dohme AG
Pfizer AG

Further Corporate Supporters

Actelion (Schweiz) AG
ALK Abello
Allergomed AG
Allmiral AG
Astellas Pharma AG
AstraZeneca AG
Bauerfeind AG
Bayer (Schweiz) AG
Biotest AG
Bristol-Myers Squibb AG
Coloplast AG
CSL Behring (Schweiz) AG
Dermapharm AG
Drossa Pharm AG
Ganzoni & Cie AG
Gebro Pharma AG
Geistlich Pharma AG
Glaxo Smith Kline AG
J-P, F & E Hottinger & Co, Effektenhändler
IBSA Institut Biochimique SA
Johnson & Johnson Medical
Meda Pharma GmbH
Mundipharma Medical Company SA
Novartis (Schweiz) AG
Permamed AG
Qualicare AG
Roche Pharma (Schweiz) AG
Servier (Suisse) SA
Smith & Nephew AG
Trimedal AG
Waldmann Lichttechnik GmbH
Valucept



Charitable foundations closely associated with the Department of Dermatology USZ

Bruno Bloch Stiftung

Secretariat:
Dermatologische Klinik, Direktion
UniversitätsSpital Zurich
Gloriastrasse 31
8091 Zurich
brunoblochstiftung@usz.ch

Bank details:
UBS AG
8091 Zurich
Bank account No. 206-P0238697.0
Keyword "BrunoBlochStiftung"
IBAN: CH 59 0020 6206 P023 8697 0
SWIFT: UBSWCHZH80A
Clearing-No.: 298

Verein für Hautkrebsforschung

Secretariat:
Dermatologische Klinik
UniversitätsSpital Zurich
Gloriastrasse 31
8091 Zurich
info@skincancer.ch, www.skincancer.ch

Bank details:
Jean-Philippe, François & Emmanuel Hottinger & Co.,
Effektenhändler, Zurich

Bank: Credit Suisse Zurich
Swift: CRESCHZZ80A
Clearing-No.: 4835
Beneficiary: Verein für Hautkrebsforschung
Account CHF: IBAN: CH80 0483 5076 6289 5100 0
Reference: ALO 426

Guest Speakers of our Department in 2013 and 2014

Anliker	Mark	MD	Department of Dermato-Allergology, University Hospital St. Gallen, CH	Clinical Pearls
Argenziano	Giuseppe	Prof.	Department of Dermatology, Second University Hospital Naples, IT	Spitz/Reed Nevi (Dermatoscopy Course), Clues not to miss melanoma
Ballmer	Kurt	MD	Paul Scherer Institute CH	Structural and functional analysis of VEGF signaling in angiogenesis: or how basic research led to the discovery of new, highly specific receptor-inhibitory molecules
Banholzer	Beatrice	MD	Private Praxis, Zurich, CH	Jahresthema II: Hautanhangserkrankungen - Haartransplantationen - Indikationen, Ergebnisse, Grenzen
Bernauer	Wolfgang	Prof.	Ophthalmologist, Private Praxis, Zurich, CH	Entzündungen am und um das Auge
Beck	Bernhard	MD	Private Praxis, Zurich, CH	Kutane Leishmaniose - Diagnostik und Therapie
Betschart	Cornelia	MD	Gynäkologie, UniversitätsSpital Zürich, CH	Erkrankungen des weiblichen Genitales
Bezzola	Alain	MD	Private Praxis, Geneva, CH	Blepharoplastik
Bircher	Andreas	Prof.	Dept of Allergology, University Hospital Basel, CH	Fusculus Furiosus - Mollitiae Supra Magister
Blum	Andreas	Prof.	Private practice, Konstanz, DE	Recurrent Nevi and Mucosal Lesions (Dermatoscopy Course)
Boehncke	Wolf-Henning	Prof.	Head Department of Dermatology, HUG Geneva, CH	What's new in Psoriasis?
Borelli	Siegfried	MD	Dept of Dermatology, Stadtspital Triemli Zurich, CH	Regionale Dermatosen: Intertrigo Erkrankungen
Bruckner-Tuderman	Leena	Prof.	Universitäts-Hautklinik Freiburg, DE	Von hereditären Epidermolysen zu Hautfragilitätssyndrome - Ursachen, Mechanismen und Therapien
Brueggen	Charlotte	MD	Dermatology, Medical University of Vienna, AT	Diverse T cell responses lead to the different manifestations of cutaneous graft-versus-host disease
Burg	Günther	Prof.	Zurich, CH (retired)	Vita Prof. Dr Dr h.c. Urs Walter Schnyder
Chaloupka	Karla	MD	Dept of Ophthalmology, University Hospital Zurich, CH	Chirurgie: Onkologische Augenlidchirurgie und Orbitalchirurgie
della Torre	Rocco	MD	Dept of Dermatology, Inselspital Bern, CH	Mohs' mikrographische Chirurgie: Abschluss, Procedere
de Viragh	Pierre	MD	Private Praxis, Zurich, CH	Jahresthema II: Hautanhangserkrankungen – Management von Haarproblemen in der Praxis
Elsner	Peter	Prof.	Dept of Dermatology and Allergology, University Hospital Jena, DE	Duftstoffallergien in Europa
Eng	Peter	MD	Klinik für Kinder und Jugendliche, Kantonsspital Aarau, Aarau, CH	Immuntherapie: von Blamoutier bis heute
Gaide	Olivier	MD	Department of Dermatology, CHUV, Lausanne, CH	Quiz Fälle (Dermatoscopy Course)
Göschke	Benedikt	MD	Specialist for Skin Diseases, Bern, CH	Regionale Dermatosen: Erkrankungen bei dunkler Haut
Guggenheim	Merlin	PD	Klinik für Plastische Chirurgie und Handchirurgie, UniversitätsSpital Zürich, CH	Chirurgische Melanombehandlung
Haneke	Eckart	Prof.	Dept of Dermatology, Inselspital Bern, CH	Jahresthema II: Hautanhangserkrankungen - Chirurgie des Nagelapparates
Häusermann	Peter	PD	Dept of Dermatology, University Hospital, Basel, CH	Therapie der hartnäckigen Rosazea und POD
Hausmann	Oliver	MD	Löwenpraxis, Luzern, CH	Allergien und Intoleranzen auf Biologicals
Hertl	Michael	Prof.	Universitätsklinikum Giessen und Marburg, DE	Entzündliche Dermatosen: Pemphigoiderkrankungen
Hess	Monika	MD	Private Praxis, Zurich, CH	Mohs' mikrographische Chirurgie/Nagelchirurgie
Itin	Peter	Prof.	Dept of Dermatology, University Hospital Basel, CH	Jahresthema I: Hautanhangserkrankungen – Ektodermale Dysplasien
Jemec	Gregor	Prof.	Department of Dermatology, Roskilde Hospital, Roskilde, DK	Jahresthema Teil I: Hautanhangserkrankungen – Pathogenese und medikamentöse Therapie der Acne inversa
Kägi	Martin	MD	Private Praxis, Zurich, CH	Fillertherapie in der Praxis
Kazakov	Dmitry	Prof.	Sikl's Department of Pathology, Charles University, Medical Faculty Hospital Pilsen, CZ	Jahresthema Teil I: Hautanhangserkrankungen - Adnextumoren - benigne oder maligne? - Tumorsyndrome

Krasovec	Marguerite	MD	Private Praxis, Schlieren, CH	Lineare IgA Dermatose, IgM-Dermatose
Lautenschlager	Stephan	Prof.	Dermatol. Ambulatorium, Stadtspital Triemli, Zurich, CH	Jahresthema II: Hautanhangserkrankungen - Tumoren des Nagelapparates - Nagelchirurgie
Levine	John	Prof.	Pediatric Hematology & Oncology, C.S. Mott Children's Hospital Michigan, USA	The role of photopheresis in the pre-emptive treatment of GvHD
Lutz	Franz	MD	CHUV Lausanne, CH	Arenaviruses: from lethal immune pathology to a vaccine
Marghoob	Ash	Prof.	Memorial Sloan Kettering Cancer Center, New York, USA	2 step algorithm (Dermatoscopy Course) / Non melanocytic lesions
Martin	Roland	Prof.	Neurology, University Hospital Zurich, CH	Characteriza
Michielin	Olivier	Prof.	Professor at the Medical Faculty, University of Lausanne, SIB Molecular Modelling Group Lausanne, CH	Update Immunotherapy: Ipilimumab & PD-1
Mühlstädt	Michael	MD	Klinik u. Poliklinik für Dermatologie und Allergologie, München, DE	Elektrochemotherapie - Mohs' mikrographische Chirurgie: Nachexzisionen / Rekonstruktionen
Müller	Andreas-Paul	MD	Gastrozentrum Klinik Hirslanden Zürich, CH	Pruritus ani - diagnostische und therapeutische Aspekte
Navarini	Alexander	PD	King's College London, GB	Exom sequencing in the Dermatology
Nenoff	Pietro	Prof.	Facharzt für Haut- und Geschlechtskrankheiten, Mölvis, DE	Pilzerkrankungen: Diagnostik und Therapie
Oberholzer	Patrick	PD	Dept of Dermatology, Inselspital Bern, CH	Neue therapeutische Ansätze bei Basalzellkarzinomen
Pachlopnik	Jana	MD	Children's Hospital Zurich, CH	Biologicals for Haemophagocytic Syndromes
Philipp-Dormston	Wolfgang	MD	Hautzentrum Köln, Köln, DE	What's New 1: Neuigkeiten in der ästhetischen Medizin
Pichler	Werner	Prof.	Head Dept of Allergology, Inselspital Bern, CH	Allergien & Intoleranzen: Schwere Medikamentenreaktionen: Mechanismus und Genetik
Plaza	Tobias	MD	Center of Skin and Allergy, Uster, CH	Praxiszertifizierung: Praktische Tipps und Tricks
Röcken	Martin	Prof.	Leitung Hautklinik, Universitäts-Hautklinik Tübingen, DE	Psoriasis
Renz	Harald	Prof.	Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, DE	Nervensystem und Allergien
Rordorf	Tamara	MD	Klinik für Onkologie, UniversitätsSpital Zürich, CH	Organspezifische Besonderheiten von lymphoproliferativen Erkrankungen
Rümmelein	Bettina	MD	Fachärztin für Dermatologie, Seespital Kilchberg, CH	Workshop: Botox
Ruzicka	Thomas	Prof.	Leitung Klinik und Poliklinik für Dermatologie und Allergologie TU München, DE	Bruno Bloch-Gedächtnisvorlesung: Akne
Schaller	Martin	Prof.	Universitäts-Hautklinik Tübingen, DE	Jahresthema Teil I: Hautanhangserkrankungen - Neues zur Akne
Schäppi	Georg	MD	aha! Schweiz. Zentrum für Allergie, Haut und Asthma, Bern, CH	aha! - Eine Patientenorganisation im Wandel der Zeit
Schwarz	Thomas	Prof.	Klinik für Dermatologie, Allergologie u. Venereologie, Univ.Klinikum Schleswig-Holstein, Kiel, Deutschland	Wirkungsmechanismus der ECP
Skaria	André	MD	Specialist of Dermatology Lausanne/Vevey, CH	What's New 2: Chirurgie
Stieger	Marco	MD	Oberarzt Dermatologie, Inselspital Bern	Mohs' mikrographische Chirurgie: Nachexzisionen / Rekonstruktionen
Stuart	Darrin	MD	Novartis Schweiz, CH	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Surace	Laura	MD	Oncology, University Hospital Zurich, CH	Immune-response related pathways activated by radiotherapy and their impact on therapeutic efficacy
Thomas	Luc	Prof.	Department of Dermatology, Hospital of Dieu, Lyon, FR	Lesions of the face (Dermatoscopy Course) / Dysplastic nevi / Digital dermoscopy follow up
van den Broek	Maries	Prof.	Oncology, University Hospital Zurich, CH	Aldara is more than Imiquimod
Volz	Andreas	MD	Dermatologie, Universitätsspital Basel, CH	Mohs' mikrographische Chirurgie/Nagelchirurgie - Mohs' mikrographische Chirurgie: Nachexzisionen / Rekonstruktionen
Wüthrich	Brunello	Prof.	Zurich, CH (retired)	45 Jahre Nahrungsmittelallergien - ein Rückblick
Zalaudek	Iris	Prof.	Department of Dermatology, University Hospital Graz, A	Benign Melanocytic lesions (Dermatoscopy Course) / Dermoscopy in general dermatology
Zillikens	Detlef	Prof.	Universitätsklinikum Schleswig-Holstein, Lübeck, DE	Entzündliche Dermatosen: Pemphiguserkrankungen

15. Publications

Publications 2013

Original papers (peer-reviewed)

Accart, Nathalie; Urosevic-Maiwald, Mirjana; Dummer, Reinhard; Bataille, Vincent; Kehrer, Nadine; Niculescu, Cristina; Limacher, Jean-Marc; Chenard, Marie-Pierre; Bonnefoy, Jean-Yves; Rooke, Ronald. Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042. *Journal of Translational Medicine* 2013; 11: 226

Argenziano, Giuseppe; Giacomel, Jason; Zalaudek, Iris; Blum, Andreas; Braun, Ralph P; Cabo, Horacio; Halpern, Allan; Hofmann-Wellenhof, Rainer; Malvey, Josep; Marghoob, Ashfaq A; Menzies, Scott; Moscarella, Elvira; Pellacani, Giovanni; Puig, Susana; Rabinovitz, Harold; Saida, Toshiaki; Seidenari, Stefania; Soyer, H Peter; Stolz, Wilhelm; Thomas, Luc; Kittler, Harald. A clinico-dermoscopic approach for skin cancer screening: recommendations involving a survey of the International Dermoscopy Society. *Dermatologic Clinics* 2013; 31: 525-534, vii

Ascierto, Paolo A; Schadendorf, Dirk; Berking, Carola; Agarwala, Sanjiv S; van Herpen, Carla M; Queirolo, Paola; Blank, Christian U; Hauschild, Axel; Beck, J Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zube, Angela; Dummer, Reinhard. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. *Lancet Oncology* 2013; 14: 249-256

Assaf, Chalid; Becker, Jürgen C; Beyer, Marc; Cozzio, Antonio; Dippel, Edgar; Klemke, Claus-Detlev; Kurschat, Peter; Weichenthal, Michael; Stadler, Rudolf. Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin--consensus of the lymphoma group of the Working Group Dermatologic Oncology. *JDDG - Journal der Deutschen Dermatologischen Gesellschaft* 2013; 11: 338-347

Badertscher, N; Braun, R P; Held, U; Kofmehl, R; Senn, O; Hofbauer, G F; Rossi, P O; Wensing, M J; Rosemann, T; Tandjung, R. Diagnostic competence of Swiss general practitioners in skin cancer. *Swiss Medical Weekly* 2013; 143: w13834

Baeyens, Audrey; Pérol, Louis; Fourcade, Gwladys; Cagnard, Nicolas; Carpentier, Wassila; Woytschak, Janine; Boyman, Onur; Hartemann, Agnès; Piaggio, Eliane. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. *Diabetes* 2013; 62: 3120-3131

Barysch, Marjam J; Weibel, Lisa; Neuhaus, Kathrin; Subotic, Ulrike; Schäfer, Leo; Donghi, Davide; Hafner, Juerg; Braun, Ralph; Lächli, Severin; Dummer, Reinhard; Schiestl, Clemens.

Dermatofibrosarcoma protuberans in childhood treated with slow Mohs micrographic surgery. *Pediatric Dermatology* 2013; 30: 462-468

Bas, M; Greve, J; Hoffmann, T K; Reshef, A; Aberer, W; Maurer, M; Kivity, S; Farkas, H; Floccard, B; Arcoleo, F; Martin, L; Sitkauskienė, B; Bouillet, L; Schmid-Grendelmeier, P; Li, H; Zanichelli, A. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. *Allergy* 2013; 68: 1452-1459

Basset-Seguín, N; Baumann Conzett, K; Gerritsen, M J P; Gonzalez, H; Haedersdal, M; Hofbauer, G F L; Aguado, L; Kerob, D; Lear, J T; Piaserico, S; Ulrich, C. Photodynamic therapy for actinic keratosis in organ transplant patients. *Journal of the European Academy of Dermatology and Venereology* 2013; 27: 57-66

Bekou, V; Baltisser, I; Dummer, R; Traber, J. Ulkus plantar bei multimorbidem Patienten. *Der Chirurg* 2013; 84: 222-224

Belloni, Benedetta; Lambertini, Chiara; Nuciforo, Paolo; Phillips, Jay; Bruening, Eric; Wong, Stephane; Dummer, Reinhard. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system. *Journal of Clinical Pathology* 2013; 66: 124-135

Berneburg, M; Herzinger, T; Rampf, J; Hoetzenecker, W; Guenova-Hötzenecker, E; Meisner, C; Maetzke, J; Schaefer, T; Eberlein, B; Scharffetter-Kochanek, K; Rocken, M. Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study. *British Journal of Dermatology* 2013; 169: 704-708

Bhattacharya, Indranil; Dräger, Katja; Albert, Verena; Contasot, Emmanuel; Damjanovic, Marlen; Hagiwara, Asami; Zimmerli, Lukas; Humar, Rok; Hall, Michael N; Bättegay, Edouard J; Haas, Elvira. Rictor in perivascular adipose tissue controls vascular function by regulating inflammatory molecule expression. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2013; 33: 2105-2111

Biedermann, L; Kerl, K; Rogler, G; Hofbauer, G F L. Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease. *Inflammatory Bowel Diseases* 2013; 19: E4-6

Boi, Michela; Rinaldi, Andrea; Kwee, Ivo; Bonetti, Paola; Piva, Roberto; Rancoita, Paola M V; et al.,. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. *Blood* 2013; 122: 2683-2693

- Bosshard, Philipp P. Usefulness of IgM-specific enzyme immunoassays for serodiagnosis of syphilis: comparative evaluation of three different assays. *Journal of Infection* 2013; 67: 35-42
- Bouchaud, Grégory; Gehrke, Samuel; Krieg, Carsten; Kolios, Antonios; Hafner, Jürg; Navarini, Alexander A; French, Lars E; Boyman, Onur. Epidermal IL-15 α acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. *Journal of Experimental Medicine* 2013; 210: 2105-2117
- Braun, Ralph P; Thomas, L; Dusza, S W; Gaide, O; Menzies, S; Dalle, S; Blum, A; Argenziano, G; Zalaudek, I; Kopf, A; Rabinovitz, H; Oliviero, M; Perrinaud, A; Cabo, H; Pizzichetta, M; Pozo, L; Langford, D; Tanaka, M; Saida, T; Perusquia Ortiz, A M; Kreusch, J; De Giorgi, V; Piccolo, D; Grichnik, J M; Kittler, H; Puig, S; Malvey, J; Seidenari, S; Stanganelli, I; French, L; Marghoob, A A. Dermoscopy of acral melanoma: a multicenter study on behalf of the international dermoscopy society. *Dermatology* 2013; 227: 373-380
- Cippà, Pietro E; Kamarashev, Jivko; Chen, Jin; Kraus, Anna K; Segerer, Stephan; Feldmeyer, Laurence; Fehr, Thomas. Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A. *Apoptosis* 2013; 18: 315-323
- Cox, Linda; Compalati, Enrico; Kundig, Thomas; Larche, Mark. New directions in immunotherapy. *Current Allergy and Asthma Reports* 2013; 13: 178-195
- Cozzio, A; French, L E. Genodermatosen. *Der Hautarzt* 2013; 64: 5-6
- Cronin, Julia C; Watkins-Chow, Dawn E; Incao, Art; Hasskamp, Joanne H; Schönewolf, Nicola; Aoude, Lauren G; Hayward, Nicholas K; Bastian, Boris C; Dummer, Reinhard; Loftus, Stacie K; Pavan, William J. SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis. *Cancer Research* 2013; 73: 5709-5718
- Dalton, Lucy E; Kamarashev, Jivko; Barinaga-Rementería Ramirez, Irene; White, Gavin; Malliri, Angeliki; Hurlstone, Adam. Constitutive RAC activation is not sufficient to initiate melanocyte neoplasia but accelerates malignant progression. *Journal of Investigative Dermatology* 2013; 133: 1572-1581
- Das Thakur, Meghna; Salangsang, Fernando; Landman, Allison S; Sellers, William R; Pryer, Nancy K; Levesque, Mitchell P; Dummer, Reinhard; McMahon, Martin; Stuart, Darrin D. Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. *Nature* 2013; 494: 251-255
- de Respínis, Sophie; Tonolla, Mauro; Pranghofer, Sigrid; Petrini, Liliane; Petrini, Orlando; Bosshard, Philipp P. Identification of dermatophytes by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Medical Mycology* 2013; 51: 514-521
- DeSimone, Jennifer A; Guenova-Hötzenecker, Emmanuella; Carter, Joi B; Chaney, Keri S; Aldridge, Julie R; Noell, Claire M; Dorosario, Andrew A; Hansen, Jorgen L; Kupper, Thomas S; Devlin, Phillip M. Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology* 2013; 69: 61-65
- Döbbeling, Udo; Waeckerle-Men, Ying; Zabel, Franziska; Graf, Nicole; Kundig, Thomas M; Johansen, Pål. The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. *Experimental Dermatology* 2013; 22: 119-124
- Dummer, R; Mangana, J. Carboplatin, paclitaxel and sorafenib in advanced melanoma - what have we learned?. *Translational Cancer Research* 2013; 2: 46-47
- Duvic, Madeleine; Dummer, Reinhard; Becker, Jürgen C; Poulalhon, Nicolas; Ortiz Romero, Pablo; Grazia Bernengo, Maria; Lebbé, Celeste; Assaf, Chalid; Squier, Margaret; Williams, Denise; Marshood, Miriam; Tai, Feng; Prince, H Miles. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. *European Journal of Cancer* 2013; 49: 386-394
- Feldmeyer, Laurence; Shojaati, Golnar; Spanaus, Katharina-Susanne; Navarini, Alexander; Theler, Barbara; Donghi, Davide; Urosevic-Maiwald, Mirjana; Glatz, Martin; Imhof, Laurence; Barysch, Marjam J; Dummer, Reinhard; Roos, Malgorzata; French, Lars E; Surber, Christian; Hofbauer, Günther F L. Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3. *Journal of the American Academy of Dermatology* 2013; 69: 530-536
- Geier, J; Lessmann, H; Skudlik, C; Ballmer-Weber, B K; Weisshaar, E; Uter, W; Schnuch, A. Berufsbedingte Kontaktallergie bei Maurern, Fliesenlegern und Angehörigen verwandter Berufe. *Allergologie* 2013; 36: 252-266
- Geier, Johannes; Ballmer-Weber, Barbara K; Dickel, Heinrich; Frosch, Peter J; Bircher, Andreas; Weisshaar, Elke; Hillen, Uwe. Monitoring contact sensitization to p-phenylenediamine (PPD) by patch testing with PPD 0.3% in petrolatum. *Contact Dermatitis* 2013; 69: 26-31
- Glatz, M; Achermann, Y; Kerl, K; Bosshard, P P; Cozzio, A. Nodular secondary syphilis in a woman. *BMJ Case Reports* 2013; 2013: 1-5
- Glatz, M; Schmid-Grendelmeier, P. Bettle Dermatitis. *Imported Skin Disease* 2013; 273-282
- Guenova-Hötzenecker, Emmanuella; Hoetzenecker, Wolfram; Kisuze, Geoffrey; Teske, Anna; Heeg, Peter; Voykov, Bogomil; Hoetzenecker, Konrad; Schippert, Wilfried; Moehrl, Matthias. Banana leaves as an alternative wound dressing. *Dermatologic Surgery* 2013; 39: 290-297

- Guenova-Hötzenecker, Emmanuella; Watanabe, Rei; Teague, Jessica E; Desimone, Jennifer A; Jiang, Ying; Dowlatshahi, Mitra; Schlapbach, Christoph; Schaeckel, Knut; Rook, Alain H; Tawa, Marianne; Fisher, David C; Kupper, Thomas S; Clark, Rachael A. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. *Clinical Cancer Research* 2013; 19: 3755-3763
- Hafner, J; Geiges, M L; Burg, G; French, L E. Zürich stellt sich vor: Eine beachtliche Geschichte - ein beachtlicher Leistungsausweis. *Dermatologie Praxis* 2013; 20-22
- Hoetzenecker, K; Mitterbauer, A; Guenova-Hötzenecker, E; Schweiger, T; Altmann, P; Zimmermann, M; Hofbauer, H; Beer, L; Klepetko, W; Ankersmit, H J. High levels of lung resident CD4+CD28null cells in COPD: implications of autoimmunity. *Wiener klinische Wochenschrift* 2013; 125: 150-155
- Hoetzenecker, Wolfram. Transkriptionsfaktor ATF3 zur Differenzierung der Sepsis? Besteht die Sepsis aus unterschiedlichen Entitäten? *Intensiv-News* 2013; 12-13
- Hoetzenecker, Wolfram; Guenova-Hötzenecker, Emmanuella; Mitev, Vanyo; Schanz, Stefan; Ulmer, Anja; Fierlbeck, Gerhard. Treatment of pyoderma gangrenosum with topical factor XIII. *European Journal of Dermatology* 2013; 23: 653-657
- Hompes, S; Grünhagen, J; Schmid-Grendelmeier, P; Michel, S; Worm, M. Seltene Nahrungsmittelallergene - Daten aus dem Anaphylaxie-Register. *Allergologie* 2013; 36: 204-209
- Iolyeva, Maria; Aebischer, David; Proulx, Steven T; Willrodt, Ann-Helen; Ecoiffier, Tatiana; Häner, Simone; Bouchaud, Grégory; Krieg, Carsten; Onder, Lucas; Ludewig, Burkhard; Santambrogio, Laura; Boyman, Onur; Chen, Lu; Finke, Daniela; Halin, Cornelia. Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage. *Blood* 2013; 122: 2271-2281
- Jaimes, Natalia; Chen, Lucy; Dusza, Stephen W; Carrera, Cristina; Puig, Susana; Thomas, Luc; Kelly, John W; Dang, Lucy; Zalaudek, Iris; Braun, Ralph P; Menzies, Scott W; Busam, Klaus J; Marghoob, Ashfaq A. Clinical and dermoscopic characteristics of desmoplastic melanomas. *JAMA Dermatology* 2013; 149: 413-421
- Jaimes, Natalia; Dusza, Stephen W; Quigley, Elizabeth A; Braun, Ralph P; Puig, Susana; Malvey, Josep; Kittler, Harald; Rabinovitz, Harold S; Oliviero, Margaret C; Soyer, H Peter; Grichnik, James M; Korzenko, Adam; Cabo, Horacio; Carlos-Ortega, Blanca; Ahlgrim-Siess, Verena; Kopf, Alfred W; Marghoob, Ashfaq A. Influence of time on dermoscopic diagnosis and management. *The Australasian Journal of Dermatology* 2013; 54: 96-104
- Jankovic, Dragana; Ganesan, Jayanthi; Bscheider, Michael; Stickel, Natalie; Weber, Felix C; Guarda, Greta; Follo, Marie; Pfeifer, Dietmar; Tardivel, Aubry; Ludigs, Kristina; Bouazzaoui, Abdellatif; Kerl, Katrin; Fischer, Julius C; Haas, Tobias; Schmitt-Gräff, Annette; Manoharan, Anand; Müller, Leonard; Finke, Jürgen; Martin, Stefan F; Gorka, Oliver; Peschel, Christian; Ruland, Jürgen; Idzko, Marco; Duyster, Justus; Holler, Ernst; French, Lars E; Poeck, Hendrik; Contassot, Emmanuel; Zeiser, Robert. The Nlrp3 inflammasome regulates acute graft-versus-host disease. *Journal of Experimental Medicine* 2013; 210: 1899-1910
- Jenni, D; Hofbauer, G F L. Carcinome spinocellulaire - un cancer blanc de la peau ne vient que rarement seul. *Swiss Medical Forum = Schweizerisches Medizin-Forum* 2013; 13: 814-817
- Jungraithmayr, Wolfgang; Codarri, Laura; Bouchaud, Gregory; Krieg, Carsten; Boyman, Onur; Gyölvézi, Gabor; Becher, Burkhard; Weder, Walter; Münz, Christian. Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells. *American Journal of Respiratory and Critical Care Medicine* 2013; 187: 1349-1359
- Kaiser, Dominik; Hafner, Jürg; Mayer, Dieter; French, Lars E; Läubli, Severin. Alginate dressing and polyurethane film versus paraffin gauze in the treatment of split-thickness skin graft donor sites: a randomized controlled pilot study. *Advances in Skin & Wound Care* 2013; 26: 67-73
- Kempf, Werner; Flaig, Michael J; Kutzner, Heinz. Molecular diagnostics in infectious skin diseases. *JDDG - Journal der Deutschen Dermatologischen Gesellschaft* 2013; 11: 50-58
- Kempf, Werner; Kazakov, Dmitry V; Baumgartner, Hans-Peter; Kutzner, Heinz. Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings. *Journal of the American Academy of Dermatology* 2013; 68: 809-816
- Kempf, Werner; Kazakov, Dmitry V; Cozzio, Antonio; Kamarshev, Jivko; Kerl, Katrin; Plaza, Tobias; Metze, Dieter. Primary cutaneous CD8+ small- to medium-sized Lymphoproliferative disorder in extrafacial sites: Clinicopathologic features and concept on their classification. *American Journal of Dermatology* 2013; 35: 159-166
- Kempf, Werner; Kazakov, Dmitry V; Kutzner, Heinz. Lobular Panniculitis due to *Borrelia burgdorferi* infection mimicking subcutaneous panniculitis-like T-Cell Lymphoma. *American Journal of Dermatopathology* 2013; 35: e30-3
- Kempf, Werner; Kazakov, Dmitry V; Schäfer, Leo; Rütten, Arno; Mentzel, Thomas; Paredes, Bruno E; Palmedo, Gabriele; Panizon, Renato G; Kutzner, Heinz. Angioinvasive Lymphomatoid

- Papulosis: A new variant simulating aggressive lymphomas. *American Journal of Surgical Pathology* 2013; 37: 1-13
- Kerl, Katrin; Leo, Schärer; Hesse, Raphael; Hesse, Benedikt; Gabriela, Palmedo; Requena, Luis; Wiesner, Thomas; Kutzner, Heinz. Two-dimensional visualization of multicolor FISH-generated data as a helpful tool for the analysis and understanding of cytogenetic and chromosomal alterations in melanocytic lesions. *American Journal of Dermatopathology* 2013; 35: 151-158
- Klimek, L; Willers, J; Schendzielorz, P; Kündig, T M; Senti, G. Immuntherapie der allergischen Rhinitis ohne Allergene? : Neue Möglichkeiten einer Immunmodulation durch Vakzini-erung mittels „virus-like particles“ und CpG-Motiven. *HNO* 2013; 61: 826-833
- Knapik, Alicia; Kornmann, Kai; Kerl, Katrin; Calcagni, Maurizio; Contaldo, Claudio; Vollmar, Brigitte; Giovanoli, Pietro; Lindenblatt, Nicole. Practice of split-thickness skin graft storage and histological assessment of tissue quality. *Journal of Plastic, Reconstructive & Aesthetic Surgery* 2013; 66: 827-834
- Kolios, Antonios G A; Marques Maggio, Ewerton; Gubler, Christoph; Cozzio, Antonio; Dummer, Reinhard; French, Lars E; Navarini, Alexander A. Oral, esophageal and cutaneous lichen ruber planus controlled with alitretinoin: case report and review of the literature. *Dermatology* 2013; 226: 302-310
- Kolm, I; Pawlik, E; Eggmann, N; Kamarachev, J; Kerl, K; French, L E; Hofbauer, G F L. Subacute cutaneous lupus erythematosus triggered by radiotherapy. *Case Reports in Dermatology* 2013; 5: 232-235
- Konstantinou, G N; Asero, R; Ferrer, M; Knol, E F; Maurer, M; Raap, U; Schmid-Grendelmeier, P; Skol, P S; Grattan, C E H. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. *Allergy* 2013; 68: 27-36
- Läuchli, S; Bayard, I; Hafner, J; Hunziker, T; Mayer, D; French, L. Unterschiedliche Abheilungsdauer und Häufigkeit der Hospitalisation bei Ulcus cruris verschiedener Ursachen. *Der Hautarzt* 2013; 64: 917-922
- Le, Thuy-My; Bublin, Merima; Breiteneder, Heimo; Fernández-Rivas, Montserrat; Asero, Riccardo; Ballmer-Weber, Barbara; Barreales, Laura; Bures, Peter; Belohlavkova, Simona; de Blay, Frédéric; Clausen, Michael; Dubakiene, Ruta; Gislason, David; van Hoffen, Els; Jedrzejczak-Czechowicz, Monika; Kowalski, Marek L; Kralimarkova, Tanya; Lidholm, Jonas; Dewitt, Asa Marknell; Mills, Clare E N; Papadopoulos, Nikolaos G; Popov, Todor; Purohit, Ashok; van Ree, Ronald; Seneviratne, Suranjith; Sinaniotis, Athanasios; Summers, Colin; Vázquez-Cortés, Sonia; Vieths, Stefan; Vogel, Lothar; Hoffmann-Sommergruber, Karin; Knulst, André C. Kiwifruit allergy across Europe: Clinical manifestation and IgE recognition patterns to kiwifruit allergens. *Journal of Allergy and Clinical Immunology* 2013; 131: 164-171
- Lefort, Karine; Brooks, Yang; Ostano, Paola; Cario-André, Muriel; Calpini, Valérie; Guinea-Viniegra, Juan; Albinger-Hegyí, Andrea; Hoetzenecker, Wolfram; Kolfshoten, Ingrid; Wagner, Erwin F; Werner, Sabine; Dotto, Gian Paolo. A miR-34a-SIRT6 axis in the squamous cell differentiation network. *EMBO Journal Online* 2013; 32: 2248-2263
- Menzies, Scott W; Moloney, Fergal J; Byth, Karen; Avramidis, Michelle; Argenziano, Giuseppe; Zalaudek, Iris; Braun, Ralph P; Malvey, Josep; Puig, Susana; Rabinovitz, Harold S; Oliviero, Margaret; Cabo, Horacio; Bono, Riccardo; Pizzichetta, Maria A; Claeson, Magdalena; Gaffney, Daniel C; Soyer, H Peter; Stanganelli, Ignazio; Scolyer, Richard A; Guitera, Pascale; Kelly, John; McCurdy, Olivia; Llambrich, Alex; Marghoob, Ashfaq A; Zaballos, Pedro; Kirchesch, Herbert M; Piccolo, Domenico; Bowling, Jonathan; Thomas, Luc; Terstappen, Karin; Tanaka, Masaru; Pellacani, Giovanni; Pagnanelli, Gianluca; Ghigliotti, Giovanni; Ortega, Blanca Carlos; Crafter, Greg; Ortiz, Ana María Perusquía; Tromme, Isabelle; Karaarslan, Isil Kilinc; Ozdemir, Fezal; Tam, Anthony; Landi, Christian; Norton, Peter; Kaçar, Nida; Rudnicka, Lidia; Slowinska, Monika; Simionescu, Olga; Di Stefani, Alessandro; Coates, Elliot; Kreusch, Juergen. Dermoscopic evaluation of nodular melanoma. *JAMA Dermatology* 2013; 149: 699-709
- Meyer, Thomas; Surber, Christian; French, Lars E; Stockfleth, Eggert. Resiquimod, a topical drug for viral skin lesions and skin cancer. *Expert Opinion on Investigational Drugs* 2013; 22: 149-159
- Mitteldorf, C; Bieri, M; Wey, N; Kerl, K; Kamarachev, J; Pfaltz, M; Kutzner, H; Roncador, G; Tomasini, D; Kempf, W. Expression of PD-1 (CD279) in cutaneous B-cell lymphomas with correlation to lymphoma entities and biologic behavior. *British Journal of Dermatology* 2013; 169: 1212-1218
- Mohanna, Mosab; Distler, Oliver; Sprott, Haiko; Kündig, Thomas; French, Lars E; Hofbauer, Günther. Skin lesions in anti-Pm-Scl-70 positive systemic sclerosis-dermatomyositis overlap syndrome improve during local PUVA phototherapy. *European Journal of Dermatology* 2013; 23: 730-731
- Morand, G; Vital, D; Pézier, T; Holzmann, D; Roessle, M; Cozzio, A; Huber, G F. Merkel cell carcinoma of the head and neck: a single institutional experience. *Journal of Skin Cancer* 2013; 325086
- Muehleisen, Beda; Pazhenkottil, Aju; French, Lars E; Hofbauer, Günther F L. Nonmelanoma skin cancer in organ transplant recipients: increase without delay after transplant and subsequent acceleration. *JAMA Dermatology* 2013; 149: 618-620

- Niessner, Heike; Forschner, Andrea; Klumpp, Bernhard; Honegger, Jürgen B; Witte, Maria; Bornemann, Antje; Dummer, Reinhard; Adam, Annemarie; Bauer, Jürgen; Tabatabai, Ghazal-eh; Flaherty, Keith; Sinnberg, Tobias; Beck, Daniela; Leiter, Ulrike; Mauch, Cornelia; Roesch, Alexander; Weide, Benjamin; Eigentler, Thomas; Schadendorf, Dirk; Garbe, Claus; Kulms, Dagmar; Quintanilla-Martinez, Leticia; Meier, Friedegund. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. *Cancer Medicine* 2013; 2: 76-85
- Nobbe, Stephan; Weibel, Lisa; Kuehne, Andreas; Gobbi, Sharon; Kerl, Katrin; Cozzio, Antonio. PLEVA pemphigoides - synchronous features of PLEVA and bullous pemphigoid. *JDDG - Journal der Deutschen Dermatologischen Gesellschaft* 2013; 11: 445-447
- Ogbah, Zighereda; Badenas, Celia; Harland, Mark; Puig-Butille, Joan A; Elliot, Fay; Bonifaci, Nuria; Guino, Elisabet; Rander-son-Moor, Julie; Chan, May; Iles, Mark M; Glass, Daniel; Brown, Andrew A; Carrera, Cristina; Kolm, Isabel; Bataille, Veronique; Spector, Timothy D; Malvey, Josep; Newton-Bishop, Julia; Pujana, Miquel A; Bishop, Tim; Puig, Susana. Evaluation of PAX3 genetic variants and nevus number. *Pigment Cell & Melanoma Research* 2013; 26: 666-676
- Ogbah, Zighereda; Visa, Laura; Badenas, Celia; Ríos, José; Puig-Butille, Joan Anton; Bonifaci, Nuria; Guino, Elisabet; Augé, Josep Maria; Kolm, Isabel; Carrera, Cristina; Pujana, Miquel Angel; Malvey, Josep; Puig, Susana. Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona: 25-hydroxyvitamin D3 levels and VDR variants in melanoma patients from Barcelona. *BMC Medical Genetics* 2013; 14: 1-13
- Panda, R; Ariyaratna, H; Amnuaycheewa, P; Tetteh, A; Pramod, S N; Taylor, S L; Ballmer-Weber, B K; Goodman, R E. Challenges in testing genetically modified crops for potential increases in endogenous allergen expression for safety. *Allergy* 2013; 68: 142-151
- Pihlgren, Maria; Silva, Alberto B; Madani, Rime; Giriens, Valérie; Waeckerle-Men, Ying; Fettelschoss, Antonia; Hickman, David T; López-Deber, María Pilar; Ndao, Dorin Mlaki; Vukicevic, Marija; Buccarello, Anna Lucia; Gafner, Valérie; Chuard, Nathalie; Reis, Pedro; Piorkowska, Kasia; Pfeifer, Andrea; Kündig, Thomas M; Muhs, Andreas; Johansen, Pål. TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. *Blood* 2013; 121: 85-94
- Pizzichetta, Maria A; Talamini, Renato; Marghoob, Ash A; Soy-er, H Peter; Argenziano, Giuseppe; Bono, Riccardo; Corradin, M Teresa; De Giorgi, Vincenzo; Gonzalez, Marian A; Kolm, Isabel; Kopf, Andrew W; Malvey, Joseph; Nami, Niccolò; Oliviero, Margaret; Pellacani, Giovanni; Puig, Susana; Rabinovitz, Har- old; Rubegni, Pietro; Seidenari, Stefania; Stanganelli, Ignazio; Veronesi, Andrea; Zalaudek, Iris; Zampieri, Pierfrancesco; Menzies, Scott W. Negative pigment network: an additional dermoscopic feature for the diagnosis of melanoma. *Journal of the American Academy of Dermatology* 2013; 68: 552-559
- Preussler, Stefan; Wenzel, Norman; Braun, Ralf-Peter; Ows- chimikow, Nina; Vogel, Carlo; Deninger, Anselm; Zadok, Avi; Woggon, Ulrike; Schneider, Thomas. Generation of ultra-nar- row, stable and tunable millimeter- and terahertz- waves with very low phase noise. *Optics Express* 2013; 21: 23950-23962
- Raaijmakers, Marieke I G; Rozati, Sima; Goldinger, Simone M; Widmer, Daniel S; Dummer, Reinhard; Levesque, Mitchell P. Mel- anoma immunotherapy: historical precedents, recent successes and future prospects. *Immunotherapy* 2013; 5: 169-182
- Rinderknecht, Jeannine D; Goldinger, Simone M; Rozati, Sima; Kamarashev, Jivko; Kerl, Katrin; French, Lars E; Dummer, Reinhard; Belloni, Benedetta. RASopathic skin eruptions during vemurafenib therapy. *PLoS ONE* 2013; 8: e58721
- Robert, Caroline; Dummer, Reinhard; Gutzmer, Ralf; Lorigan, Paul; Kim, Kevin B; Nyakas, Marta; Arance, Ana; Liszkay, Gabriella; Schadendorf, Dirk; Cantarini, Mireille; Spencer, Stuart; Middleton, Mark R. Selumetinib plus dacarbazine versus pla- cebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. *Lancet Oncology* 2013; 14: 733-740
- Rolfs, Frank; Huber, Marcel; Gruber, Florian; Böhm, Friederike; Pfister, Herbert J; Bochkov, Valery N; Tschachler, Erwin; Dum- mer, Reinhard; Hohl, Daniel; Schäfer, Matthias; Werner, Sabine. Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis. *Cancer Research* 2013; 73: 3460-3469
- Rongioletti, Franco; Merlo, Giulia; Cinotti, Elisa; Fausti, Valentina; Cozzani, Emanuele; Cribier, Bernard; Metzke, Dieter; Calonje, Eduardo; Kanitakis, Jean; Kempf, Werner; Stefanato, Catherine M; Marinho, Eduardo; Parodi, Aurora. Scleromyxe- dema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. *Journal of the American Academy of Dermatology* 2013; 69: 66-72
- Rozati, Sima; Naef, Lukas; Levesque, Mitchell P; French, Lars E; Dummer, Reinhard. Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. *Journal of Immunotherapy* 2013; 36: 52-56
- Rüeff, Franziska; Przybilla, Bernhard; Biló, Maria Beatrice; Müller, Ulrich; Scheipl, Fabian; Seitz, Michael J; Aberer, Werner; Bodzenta-Lukaszyk, Anna; Bonifazi, Floriano; Campi, Paolo; Darsow, Ulf; Haeberli, Gabrielle; Hawranek, Thomas; Küchen- hoff, Helmut; Lang, Roland; Quercia, Oliviero; Reider, Norbert; Schmid-Grendelmeier, Peter; Severino, Maurizio; Sturm, Gunter Johannes; Treudler, Regina; Wüthrich, Brunello. Clinical effec-

- tiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. *PLoS ONE* 2013; 8: e63233
- Saulite, I; Voykov, B; Mehra, T; Hoetzenecker, W; Guenova-Hötzenecker, E. Incidental finding of lamellar calcification of the falx cerebri leading to the diagnosis of gorlin-goltz syndrome. *Case Reports in Dermatology* 2013; 5: 301-303
- Schmid-Grendelmeier, P. Kontaktallergien auf Duftstoffe und Kosmetika. *Der Schweizer Allergie-Ratgeber* 2013; 65-69
- Seçkin, D; Barete, S; Euvrard, S; Kempf, W; et al,. Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. *American Journal of Transplantation* 2013; 13: 2146-2153
- Stadler, Rudolf; Assaf, Chalid; Klemke, Claus-Detlev; Nashan, Dorothee; Weichenthal, Michael; Dummer, Reinhard; Sterry, Wolfram. Brief S2k guidelines - Cutaneous lymphomas. *JDDG - Journal der Deutschen Dermatologischen Gesellschaft* 2013; 11: 19-28, 20
- Tissot, Alain C; Spohn, Gunther; Jennings, Gary T; Shamshiev, Abdijapar; Kurrer, Michael O; Windak, Renata; Meier, Marco; Viesti, Miriam; Hersberger, Martin; Kündig, Thomas M; Ricci, Romeo; Bachmann, Martin F. A VLP-based vaccine against interleukin-1alpha protects mice from atherosclerosis. *European Journal of Immunology* 2013; 43: 716-722
- Urosevic-Maiwald, Mirjana; Kerl, Katrin; Harr, Thomas; Bogdan Allemann, Inja. Dapsone-induced erythema multiforme with neutropenia in a patient with linear IgA dermatosis: case report and review of the literature. *International Journal of Dermatology* 2013; 52: 1369-1371
- Viard-Leveugle, Isabelle; Gaide, Olivier; Jankovic, Dragana; Feldmeyer, Laurence; Kerl, Katrin; Pickard, Chris; Roques, Stéphanie; Friedmann, Peter S; Contassot, Emmanuel; French, Lars E. TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. *Journal of Investigative Dermatology* 2013; 133: 489-98
- Vlieg-Boerstra, B J; van de Weg, W E; van der Heide, S; Skypala, I; Bures, P; Ballmer-Weber, B K; Hoffmann-Sommergruber, K; Zauli, D; Ricci, G; Dubois, A E J. Additional indications for the low allergenic properties of the apple cultivars Santana and Elise. *Plant Foods for Human Nutrition* 2013; 68: 391-395
- von Moos, Seraina; Graf, Nicole; Johansen, Pål; Müllner, Gerhard; Kündig, Thomas M; Senti, Gabriela. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy. *International Archives of Allergy and Immunology* 2013; 160: 86-92
- Voskens, Caroline J; Goldinger, Simone M; Loquai, Carmen; Robert, Caroline; Kaehler, Katharina C; Berking, Carola; Bergmann, Tanja; Bockmeyer, Clemens L; Eigentler, Thomas; Fluck, Michael; Garbe, Claus; Gutzmer, Ralf; Grabbe, Stephan; Hauschild, Axel; Hein, Rüdiger; Hundorfean, Gheorghe; Justich, Armin; Keller, Ullrich; Klein, Christina; Mateus, Christine; Mohr, Peter; Paetzold, Sylvie; Satzger, Imke; Schadendorf, Dirk; Schlaeppli, Marc; Schuler, Gerold; Schuler-Thurner, Beatrice; Trefzer, Uwe; Ulrich, Jens; Vaubel, Julia; von Moos, Roger; Weder, Patrik; Wilhelm, Tabea; Göppner, Daniela; Dummer, Reinhard; Heinzerling, Lucie M. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. *PLoS ONE* 2013; 8: e53745
- Waeckerle-Men, Ying; Bruffaerts, Nicolas; Liang, Yuan; Jurion, Fabienne; Sander, Peter; Kündig, Thomas M; Huygen, Kris; Johansen, Pål. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against *Mycobacterium tuberculosis*. *Vaccine* 2013; 31: 1057-1064
- Waeckerle-Men, Ying; Mauracher, Andrea; Håkerud, Monika; Mohanan, Deepa; Kündig, Thomas M; Høgset, Anders; Johansen, Pål. Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses. *European Journal of Pharmaceutics and Biopharmaceutics* 2013; 85: 34-41
- Walter, Anne; Schäfer, Matthias; Ceconi, Virginia; Matter, Claudia; Urosevic-Maiwald, Mirjana; Belloni, Benedetta; Schönewolf, Nicola; Dummer, Reinhard; Bloch, Wilhelm; Werner, Sabine; Beer, Hans-Dietmar; Knuth, Alexander; van den Broek, Maries. Aldara activates TLR7-independent immune defence. *Nature Communications* 2013; 4: 1560
- Weber, Jeffrey S; Dummer, Reinhard; de Pril, Veerle; Lebbé, Celeste; Hodi, F Stephen. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. *Cancer* 2013; 119: 1675-1682
- Widmer, Daniel S; Hoek, Keith S; Cheng, Phil F; Eichhoff, Ossia M; Biedermann, Thomas; Raaijmakers, Marieke I G; Hemmi, Silvio; Dummer, Reinhard; Levesque, Mitchell P. Hypoxia contributes to melanoma heterogeneity by triggering HIF1alpha-dependent phenotype switching. *Journal of Investigative Dermatology* 2013; 133: 2436-2443
- Wüthrich, Brunello; Schmid-Grendelmeier, Peter; Schindler, Christian; Imboden, Medea; Bircher, Andreas; Zemp, Elisabeth; Probst-Hensch, Nicole. Prevalence of atopy and respiratory allergic diseases in the elderly SAPALDIA population. *International Archives of Allergy and Immunology* 2013; 162: 143-148
- Zabel, Franziska; Kündig, Thomas M; Bachmann, Martin F. Virus-induced humoral immunity: on how B cell responses are initiated. *Current Opinion in Virology* 2013; 3: 357-362

Reviews

Ballmer-Weber, B K. Die anaphylaktische Reaktion. Der Informierte Arzt 2013; 36-37

Ballmer-Weber, B. Nahrungsmittelallergien bei Erwachsenen: worum handelt es sich?. Der Schweizer Allergie-Ratgeber 2013; 17-25

Ballmer-Weber, B; Spring, Ph; Bircher, A; Simon, D. Handekzeme: praktisches Vorgehen in Diagnostik und Behandlung. Swiss Medical Forum = Schweizerisches Medizin-Forum 2013; 23: 453-458

Bosshard, Philipp P; Graf, Nicole; Knaute, Damaris Fröhlich; Kündig, Thomas; Lautenschlager, Stephan; Weber, Rainer. Response of treponema pallidum particle agglutination test titers to treatment of syphilis. Clinical Infectious Diseases 2013; 56: 463-464

Bühler, M N; Feldmeyer, L; Wüthrich, R P; French, L E; Djamei, V; Serra, A L; Hofbauer, G F L. Die edukative Website Dermaguard zur Prävention von Hautkrebs nach Organtransplantation. Praxis 2013; 102: 1415-1420

de Monchy, J G; Demoly, P; Akdis, C A; Cardona, V; Papadopoulos, N G; Schmid-Grendelmeier, P; Gayraud, J. Allergy in Europe, the blueprint. Allergy 2013; 68: 1211-1218

de Waard-van der Spek, Flora B; Andersen, Klaus E; Darsow, Ulf; Mortz, Charlotte G; Orton, David; Worm, Margitta; Muraro, Antonella; Schmid-Grendelmeier, Peter; Grimalt, Ramon; Spiewak, Radoslaw; Rudzeviciene, Odilija; Flohr, Carsten; Halken, Susanne; Fiocchi, Alessandro; Borrego, Luis M; Oranje, Arnold P. Allergic contact dermatitis in children: which factors are relevant? (review of the literature). Pediatric Allergy and Immunology 2013; 24: 321-329

Dreier, Jil; Felderer, Lea; Barysch, Marjam; Rozati, Sima; Dummer, Reinhard. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opinion on Pharmacotherapy 2013; 14: 1307-1318

Dummer, Reinhard. Treating basal-cell carcinoma in a real life setting. Lancet Oncology 2013; 14: 572-573

Dummer, Reinhard; Rozati, Sima; Guenova-Hötzenecker, Emmanuella; Cozzio, Antonio. Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas. Future Oncology (London, England) 2013; 9: 1061-1064

Franzen, Daniel; Schad, Karin; Dummer, Reinhard; Russi, Erich W. Severe acute respiratory distress syndrome due to ipilimumab. European Respiratory Journal 2013; 42: 866-868

Galliker, N; Vallelian, F; Petrusch, U; Ballmer-Weber, B K; Schmid-Grendelmeier, P. Perioperative allergische Reaktion

auf Physiogel - und Gelatine/Rindfleischallergie. Allergologie 2013; 36: 410-414

Gassner, Markus; Gehrig, Regula; Schmid-Grendelmeier, Peter. Hay fever as a Christmas gift. New England Journal of Medicine 2013; 368: 393-394

Gisler, Valentin; Schaer, Dominik; Wichmann, Werner; Kerl, Katrin; Franzen, Daniel. Kein tropisches, aber ein nicht minder exotisches Fieber. Praxis 2013; 102: 999-1003

Guenova-Hötzenecker, Emmanuella; Cozzio, Antonio. Clinical improvement upon rituximab treatment in a patient with verrucous cutaneous discoid lupus erythematosus. Dermatologica Helvetica 2013; 25: 20-24

Hafner, J. 100-Jahr-Jubiläum der Schweizerischen Gesellschaft für Dermatologie und Venerologie SGDV: Eine eindrückliche Geschichte - ein eindrücklicher Leistungsausweis. Schweizerische Ärztezeitung (SÄZ) 2013; 94: 1428

Hafner, J. La Société suisse de Dermatologie et de Vénérologie SSDV fête ses 100 ans : Un jubilé attestant d'une histoire et d'une performance impressionnantes. Schweizerische Ärztezeitung (SÄZ) 2013; 1428

Hafner, J; Bonini, S. "In der Gesellschaft herrscht ein positiver Wind". Dermatologie Praxis 2013; 18-19

Haliasos, Elena C; Kerner, Miryam; Jaimes, Natalia; Zalaudek, Iris; Malvey, Josep; Hofmann-Wellenhof, Rainer; Braun, Ralph P; Marghoob, Ashfaq A. Dermoscopy for the Pediatric Dermatologist Part III: Dermoscopy of Melanocytic Lesions. Pediatric Dermatology 2013; 30: 281-293

Haliasos, Elena C; Kerner, Miryam; Jaimes, Natalia; Zalaudek, Iris; Malvey, Josep; Lanschuetzer, Christoph M; Hinter, Helmut; Hofmann-Wellenhof, Rainer; Braun, Ralph P; Marghoob, Ashfaq A. Dermoscopy for the pediatric dermatologist, part ii: dermoscopy of genetic syndromes with cutaneous manifestations and pediatric vascular lesions. Pediatric Dermatology 2013; 30: 172-181

Haliasos, Elena C; Kerner, Miryam; Jaimes-Lopez, Natalia; Rudnicka, Lidia; Zalaudek, Iris; Malvey, Josep; Hofmann-Wellenhof, Rainer; Braun, Ralph P; Marghoob, Ashfaq A. Dermoscopy for the pediatric dermatologist part I: dermoscopy of pediatric infectious and inflammatory skin lesions and hair disorders. Pediatric Dermatology 2013, 30: 163-171

Huber, Clarissa; Trüeb, Ralph M; French, Lars E; Hafner, Jürg. Negative direct immunofluorescence and nonspecific histology do not exclude the diagnosis of dermatitis herpetiformis Duhring. International Journal of Dermatology 2013; 52: 248-249

Johansen, Pål; von Moos, Seraina; Mohanan, Deepa; Kündig, Thomas M; Senti, Gabriela. New routes for allergen immunotherapy. *Human Vaccines & Immunotherapeutics* 2012; 8:1525-1533

Keller, Martin C; French, Lars E; Hofbauer, Günther F L; Bosshard, Philipp P. Erythematous skin macules with isolation of *Trichophyton eboreum* - infection or colonisation?. *Mycoses* 2013; 56: 373-375

Kolm, I; Eggmann, N; Kamarashev, J; Kerl, K; French, L E; Hofbauer, G F L. Lichenoid Drug Eruption following Intravenous Application of Orally Formulated Diamorphine, a Semisynthetic Heroin. *Case Reports in Dermatology* 2013; 5: 176-180

Läuchli, S. Einführung in die Wundbehandlung. *Dermokrates online-Handbuch* 2013; 2.16.7.1.1

Muehleisen, Beda; Gallo, Richard L. Vitamin D in allergic disease: shedding light on a complex problem. *Journal of Allergy and Clinical Immunology* 2013; 131: 324-329

Pleimes, M; Schmid-Grendelmeier, P; Weibel, L. Neurodermitis im Kindesalter: Die frühzeitige Therapie ist matchentscheidend. *Dermatologie Praxis* 2013; 8-12

Rozati, Sima; Kerl, Katrin; Kempf, Werner; Tinguely, Marianne; Zimmermann, Dieter R; Dummer, Reinhard; Cozzio, Antonio. Spindle-cell variant of primary cutaneous follicle center lymphoma spreading to the hepatobiliary tree, mimicking Klatskin tumor. *Journal of Cutaneous Pathology* 2013; 40: 56-60

Schmid-Grendelmeier, P. Allergien in der Hausarztpraxis: Sind Sie gewappnet für den allergischen Patienten? *Hausarzt Praxis* 2013; 1

Schmid-Grendelmeier, P. Der Schweizer Allergie-Ratgeber. *Der Schweizer Allergie-Ratgeber* 2013; 6-7

Schmid-Grendelmeier, P. Ekzeme umfassend behandeln. *Dermatologie Praxis* 2013; 1

Schmid-Grendelmeier, P. Grosse Ursachenvielfalt macht Diagnose und Therapie schwierig. *Dermatologie Praxis* 2013; 1

Schmid-Grendelmeier, P; Ballmer-Weber, B. Ein Leben für Allergiker - Professor Brunello Wüthrich zum 75. Geburtstag. *Dermatologie Praxis* 2013; 25-26

Publications 2014

Alavi A, Hafner J, Dutz JP, Mayer D, Sibbald RG, Criado PR, Senet P, Callen JP, Phillips TJ, Romanelli M, Kirsner RS. Atrophie blanche: is it associated with venous disease or livedoid vasculopathy? *Adv Skin Wound Care*. 2014; 27: 518-24; quiz 525-6

Amann VC, Dreier J, Ignatova D, Kamarashev J, Kerl K, Kempf W, Pascolo S, Dummer R, Cozzio A, Guenova-Hötzenecker E. Disseminated Primary Cutaneous CD8+ Small/medium-sized Pleomorphic T-cell Lymphoma Responding to Hydroxychloroquine. *Acta Derm Venereol* 2015; 95: 602-3

Amherd-Hoekstra A, Kerl K, French LE, Hofbauer GF. Reticular Erythematous Mucinosi in an atypical pattern distribution responds to UVA1 phototherapy. *J Eur Acad Dermatol Venereol* 2014; 28: 672-3

Badertscher N, Meier M, Rosemann T, Braun R, Cozzio A, Tag B, Wensing M, Tandjung R1. The role of skin self-examination at the Swiss skin cancer day. *BMC Health Serv Res* 2014; 14: 581

Badertscher N, Tandjung R, Senn O, Kofmehl R, Held U, Rosemann T, Hofbauer GF, Wensing M, Rossi PO, Braun RP. A multifaceted intervention: no increase in general practitioners' competence to diagnose skin cancer (minSKIN) - randomized controlled trial. *J Eur Acad Dermatol Venereol* 2014 [Epub ahead of print]

Barysch MJ, Levesque MP, Cheng P, Karpova MB, Mihic-Probst D, Civenni G, Shakova O, Sommer L, Biedermann T, Scheiße C, Dummer R. Coexpression of SOX10/CD271 (p75^{NTR}) and β -Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients. *Dermatopathology* 2014; 1: 35-46

Beer HD, Contassot E, French LE. The inflammasomes in autoinflammatory diseases with skin involvement. *J Invest Dermatol* 2014; 134: 1805-10

Berkner H, Seutter von Loetzen C, Hartl M, Randow S, Gubesch M, Vogel L, Husslik F, Reuter A, Lidholm J, Ballmer-Weber B, Vieths S, Rösch P, Schiller D. Enlarging the toolbox for allergen epitope definition with an allergen-type model protein. *PLoS One* 2014;9:e111691

Bouwes Bavinck JN, Harwood CA, Genders RE, Wisgerhof HC, Plasmeijer EI, Mitchell L, Olasz EB, Mosel DD, Pokorney MS, Serra AL, Feldmeyer L, Baumann Conzett K, Piaserico S, Belloni Fortina A, Jahn K, Geusau A, Gerritsen MJ, Seckin D, Gulec AT, Cetkovska P, Ricar J, Imko-Walczuk B, Proby CM, Hofbauer GF. Pain identifies squamous cell carcinoma in organ transplant recipients: the SCOPE-ITSCC PAIN study. *Am J Transplant* 2014; 14: 668-76

Brodská P, Panzner P, Pizinger K, Schmid-Grendelmeier P. IgE-mediated sensitization to *Malassezia* in atopic dermatitis: more common in male patients and in head and neck type. *DERMATITIS* 2014; 25: 120-6

Brooks YS, Ostano P, Jo SH, Dai J, Getsios S, Dziunycz P, Hofbauer GF, Cerveny K, Chiorino G, Lefort K, Dotto GP. Multifactorial ER β and NOTCH1 control of squamous differentiation and cancer. *J Clin Invest* 2014; 124: 2260-76

- Burney PG, Potts J, Kummeling I, Mills EN, Clausen M, Dubak-iene R, Barreales L, Fernandez-Perez C, Fernandez-Rivas M, Le TM, Knulst AC, Kowalski ML, Lidholm J, Ballmer-Weber BK, Braun-Fahlander C, Mustakov T, Kralimarkova T, Popov T, Sakellariou A, Papadopoulos NG, Versteeg SA, Zuidmeer L, Akkerdaas JH, Hoffmann-Sommergruber K, van Ree R. The prevalence and distribution of food sensitization in European adults. *Allergy* 2014; 69: 365-71
- Conen KL, Fischer N, Hofbauer GF, Shafaeddin-Schreve B, Winterhalder R, Rochlitz C, Zippelius A. Cetuximab in metastatic squamous cell cancer of the skin: a swiss case series. *Dermatology* 2014; 229: 97-101
- De Respinis S, Monnin V, Girard V, Welker M, Arsac M, Cellière B, Durand G, Bosshard PP, Farina C, Passera M, van Belkum A, Petrini O, Tonolla M. Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry Using the Vitek MS System for Rapid and Accurate Identification of Dermatophytes on Solid Cultures. *J Clin Microbiol* 2014; 52: 4286-92
- Dreier J, Cheng PF, Bogdan Alleman I, Gugger A, Hafner J, Tschopp A, Goldinger SM, Levesque MP, Dummer R. Basal cell carcinomas in a tertiary referral centre- a systematic analysis. *Br J Dermatol* 2014; 171: 1066-72
- Dreno B, Urošević-Maiwald M, Kim Y, Guitart J, Duvic M, Dereure O, Khammari A, Knol AC, Derbij A, Lusky M, Didillon I, Santoni AM, Acres B, Bataille V, Chenard MP, Bleuzen P, Limacher JM, Dummer R. TG1042 (Adenovirus-interferon- γ) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. *PLoS One* 2014; 9: e83670
- Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary Syndrome). *Ann Oncol* 2014; 25: 1807-12
- Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD. Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. *Eur J Cancer* 2014; 50: 611-21
- Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP. To B-(RAF) or Not to Be. *J Invest Dermatol* 2014; 134: 1200-1
- Dziunycz PJ1, Lefort K2, Wu X3, Freiburger SN1, Neu J1, Djerbi N1, Iotzowa-Weiss G1, French LE1, Dotto GP4, Hofbauer GF1. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. *J Invest Dermatol*. 2014; 134: 1998-2004
- Engeli L, Moergeli H, Binder M, Drabe N, Meier C, Buechi S, Dummer R, Jenewein J. Resilience in patients and spouses faced with malignant melanoma. A qualitative longitudinal study. *Eur J Cancer Care (Engl)* 2014 [Epub ahead of print]
- Feldmeyer L, Baumann-Vogel H, Tournier-Lasserre E, Riant F, Jung HH, French LE, Kamarashev J. Hyperkeratotic cutaneous vascular malformation associated with familial cerebral cavernous malformations (FCCM) with KRIT1/CCM1 mutation. *Eur J Dermatol* 2014; 24: 255-7
- Flaherty KT, Hennis M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. *Lancet Oncol* 2014; 15: 297-304
- Gehrig R, Gassner M, Schmid-Grendelmeier P. Alnus 3 spaethii pollen can cause allergies already at Christmas. *Aerobiologia* 2014; DOI 10.1007/s10453-014-9360-4 (published online) Page 1–9
- Gehrke S, Otsuka A, Huber R, Meier B, Kistowska M, Fenini G, Cheng P, Dummer R, Kerl K, Contassot E, French LE. Metastatic melanoma cell lines do not secrete IL-1 β but promote IL-1 β production from macrophages. *J Dermatol Sci* 2014; 74: 167-9
- Geiges M.: Die Tagungen der Deutschen Dermatologischen Gesellschaft in der Schweiz 1906, 1963, 1985. *JDDG* 2014; 12: 19-21
- Glatz M, Juricevic N, Altwegg M, Bruisten S, Komericki P, Lautenschlager S, Weber R, Bosshard P. A multicenter prospective trial to assess a new real-time polymerase chain reaction for detection of *Treponema pallidum*, *Herpes simplex-1/2* and *Haemophilus ducreyi* in genital, anal and oropharyngeal ulcers. *Clin Microbiol Infect* 2014; 20: 1020-7
- Graeni N, Buset C, Dziunycz P, Frauchiger AL, Kaufmann F, Jaberg N, Luder C, Mohanna MT, Stieger P, Weber B, Mayer D, Laeuchli S, Hafner J. Wundschmerz Phlebologie 6 2014; 43: 317-20
- Graf N, Dinkel B, Rose H, Hothorn LA, Gerhard D, Johansen P, Kündig TM, Klimek L, Senti G. A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials. *Rhinology* 2014; 52: 137-141
- Guenova-Hötzenecker E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold? *Expert Opin Invest Drugs* 2014; 23: 457-67

- Guenova-Hötzenecker E, Schanz S, Hoetzenecker W, Desimone JA, Mehra T, Voykov B, Urošević-Maiwald M, Berneburg M, Dummer R, French LE, Kerl K, Kamarachev J, Fierlbeck G, Cozzio A. Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. *Br J Dermatol* 2014; 171: 891-4
- Hafner J, Buset C, Dziunycz P, Graeni N, Kaufmann F, Jaberg N, Luder C, Mohanna MT, Stieger P, Weber B, Mayer D, Laeuchli S, Frauchiger AL. Komplexes regionales Schmerzsyndrom (CRPS). *Phlebologie* 2014; 43: 312-16
- Hafner J, Dziunycz P, Frauchiger AL, Graeni N, Kaufmann F, Jaberg N, Luder C, Mohanna MT, Stieger P, Weber B, Mayer D, Laeuchli S, Buset C. Restless-Legs-Syndrom. *Phlebologie* 2014; 43: 309-11
- Hafner J. Liebe Deutsche Dermatologische Gesellschaft, herzlichen Glückwunsch zum 125. Geburtstag! *J Dtsch Dermatol Ges* 2014; 12: 9-10
- Håkerud M, Waeckerle-Men Y, Selbo PK, Kündig TM, Høgset A, Johansen P. Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen. *J Control Release* 2014; 174: 143-150
- Hötzenecker W, Guenova-Hötzenecker E, Krug M, Goetz A, Amarov B, Haefner HM, Breuninger H. Parental anxiety and concern for children undergoing dermatological surgery. *J Dermatolog Treat* 2014 25: 367-70
- Huber C, French LE, Hafner J. Response to letter to the editor on skin manifestations of celiac disease: not always dermatitis herpetiformis. *Int J Dermatol* 2014; 53: e383-4
- Imhof L, Dummer R. Iatrogene Tätowierung nach Eiseninfusion. *Schweiz Med Forum* 2014; 14: 750-751
- Imhof K, Probst E, Seifert B, Regenass S, Schmid-Grendelmeier P. Ash pollen allergy: reliable detection of sensitization on the basis of IgE to Ole e1. *Allergo J* 2014; 23: 78-83
- Johansen P, Kündig TM. Intralymphatic immunotherapy and vaccination in mice. *J Visualized Exp* 2014; 84: e51031
- Kaesler S, Volz T, Skabytska Y, Köberle M, Hein U, Chen KM, Guenova-Hötzenecker E, Wölbling F, Röcken M, Biedermann T. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. *J Allergy Clin Immunol* 2014; 134: 92-9
- Kasper RS, Flueckiger B, Gobbi S, Lautenschlager S, Borelli S: Hydroxychloroquine-induced hyperpigmentation. *J Dtsch Dermatol Ges* 2014; 12: 158-61
- Kasper RS, Nobbe S. Images in clinical medicine. Papillomatosis cutis lymphostatica. *N Engl J Med* 2014; 370: 69
- Kempf W, Kazakov DV, Rütten A, Rupec RA, Talarcik P, Ballová V, Kerl K, Dummer R, Lautenschlager S, Zimmermann DR, Tinguely M. Primary cutaneous follicle center lymphoma with diffuse CD30 expression: A report of 4 cases of a rare variant. *J Am Acad Dermatol* 2014; 71: 548-54
- Kerl K, Wolf IH, Cerroni L, Wolf P, French LE, Kerl H. Hemophagocytosis in Cutaneous Autoimmune Disease. *Am J Dermatopathol* 2014 [Epub ahead of print]
- Kieliger S, Glatz M, Cozzio A, Bosshard PP. Tinea capitis and tinea faciei in the Zurich area – an 8-year survey of trends in the epidemiology and treatment patterns. *J Eur Acad Dermatol Venereol* [Epub ahead of print]
- Kistowska M1, Fenini G, Jankovic D, Feldmeyer L, Kerl K, Bosshard P, Contassot E, French LE. Malassezia yeasts activate the NLRP3 inflammasome in antigen-presenting cells via Syk-kinase signalling. *Exp Dermatol* 2014; 23: 884-9
- Kistowska M1, Gehrke S1, Jankovic D1, Kerl K1, Fettelschoss A1, Feldmeyer L1, Fenini G1, Kolios A1, Navarini A1, Ganceviciene R2, Schaubert J3, Contassot E1, French LE1 IL-1 β drives inflammatory responses to propionibacterium acnes in vitro and in vivo. *J Invest Dermatol* 2014 Mar; 134: 677-85
- Klimek L, Bachmann MF, Senti G, Kündig TM. Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. *Expert Rev Clin Immunol*. 2014; 10: 1059-67
- Kolm I, Aceto L, Hombach M, Kamarshv J, Hafner J, Urošević-Maiwald M. Cervicofacial actinomycosis: a long forgotten infectious complication of immunosuppression - report of a case and review of the literature. *Dermatol Online J* 2014; 20: 22640
- Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF. Is The Allergen Really Needed in Allergy Immunotherapy? *Current Treatment Options in Allergy*; 2015; 2: 72-82
- Kurinna S, Schäfer M, Ostano P, Karouzakis E, Chiorino G, Bloch W, Bachmann A, Gay S, Garrod D, Lefort K, Dotto GP, Beer HD, Werner S. A novel Nrf2-miR-29-desmocollin-2 axis regulates desmosome function in keratinocytes. *Nat Commun* 2014; 5: 5099
- Läuchli S, Vannotti S, Hafner J, Hunziker T, French L. A plant-derived wound therapeutic for cost-effective treatment of post-surgical scalp wounds with exposed bone. *Forsch Komplementmed* 2014; 21: 88-93
- Läuchli S1, Vannotti S, Hafner J, Hunziker T, French L. A plant-derived wound therapeutic for cost-effective treatment of post-surgical scalp wounds with exposed bone. *Forsch Komplementmed* 2014; 21: 88-93

- Le TM, Kummeling I, Dixon D, Barreales LT, Ballmer-Weber, BK, Clausen M, Gowland MH, Majkowska-Wojciechowska B, Mustakov T, Papadopoulos NG, Knulst AC, Potts J, Stukas R, Burney P. Low preparedness for food allergy as perceived by school staff: a EuroPrevall survey across Europe. *J Allergy Clin Immunol Pract* 2014; 2: 480-2
- Lenggenhager D, Curioni-Fontecedro A, Storz M, Shakhova O, Sommer L, Widmer DS, Seifert B, Moch H, Dummer R, Michic-Probst D. An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. *Transl Oncol* 2014; 7: 206-12
- Liu M, Johansen P, Zabel F, Leroux JC, Gauthier M. Semi-permeable coatings fabricated from comb-polymers efficiently protect proteins in vivo. *Nat Commun* 2014; 5: 5526
- McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol* 2014; 15: 323-32
- McCusker M1, Basset-Seguin N2, Dummer R3, Lewis K4, Schadendorf D5, Sekulic A6, Hou J7, Wang L7, Yue H7, Hauschild A8. Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. *Eur J Cancer* 2014; 50: 774-783
- Mehra T, Grözinger G, Mann S, Guenova-Hötzenecker E, Moos R, Röcken M, Claussen CD, Dummer R, Clasen S, Naumann A, Garbe C. Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. *PLoS One* 2014;9:e112535
- Mehra T, Ikenberg K, Moos RM, Benz R, Nair G, Schanz U, Haralambieva E, Hoetzenecker W, Dummer R, French LE, Guenova-Hötzenecker E, Cozzio A. Brentuximab as a Treatment for CD30+ Mycosis Fungoides and Sézary Syndrome. *JAMA Dermatol* 2015; 151: 73-7
- Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Beyer K, Bindslev-Jensen C, Cardona V, Dubois A, duToit G, Eigenmann P, Fernandez Rivas M, Halken S, Hickstein L, Høst A, Knol E, Lack G, Marchisotto J, Niggemann B, Nwaru BI, Papadopoulos NG, Poulsen LK, Santos AF, Skypala I, Schoepfer A, Van Ree R, Venter C, Worm M, Vlieg-Boerstra B, Panesar S, de Silva D, Soares-Weiser K, Sheikh A, Ballmer-Weber BK, Nilsson C, de Jong NW, Akdis CA; EAACI Food Allergy and Anaphylaxis Guidelines Group. EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy. *Allergy* 2014; 69: 1008-25
- Nägeli M, Fasshauer M, Sommerfeld J, Fendel A, Brandi G, Stover JF. Prolonged continuous intravenous infusion of the dipeptide L-alanine- L-glutamine significantly increases plasma glutamine and alanine without elevating brain glutamate in patients with severe traumatic brain injury. *Crit Care* 2014;18:R139
- Nägeli MC, Dummer R. Vismodegib (Erivedge®). *Schweiz Med Forum* 2014; 14: 284-286
- Nobbe S, Hafner J. [Martorell Hypertensive Ischaemic Leg Ulcer]. *Zentral BI Chir* 2014 [Epub ahead of print]
- Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. *N Engl J Med*. 2014 [Epub ahead of print]
- Rodon J, Tawbi HA, Thomas AL, Stoller R, Turttschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A Phase 1, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Hedgehog Inhibitor Sonidegib (LDE225) in Patients With Advanced Solid Tumors. *Clin Cancer Res* 2014; 20: 1900-1909
- Rozati S, Kempf W, Ostheeren-Michaelis S, Bode-Lesniewska B, Zimmermann DR, Dummer R, Cozzio A. Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. *J Clin Oncol* 2014 [Epub ahead of print]
- Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefevre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. *Ann Oncol* 2014; 25: 700-6
- Schäfer M, Willrodt AH, Kurinna S, Link AS, Farwanah H, Geusau A, Gruber F, Sorg O, Huebner AJ, Roop DR, Sandhoff K, Saurat JH, Tschachler E, Schneider MR, Langbein L, Bloch W, Beer HD, Werner S. Activation of Nrf2 in keratinocytes causes chloracne (MADISH)-like skin disease in mice. *EMBO Mol Med* 2014; 6: 442-57
- Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schaden-

- dorf D; DeCOG. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. *Ann Oncol* 2014; 25: 747-53
- Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova-Hötzenecker E, Teague JE, Campbell L, Yawalkar N, Kupper TS, Clark RA. Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. *Sci Transl Med* 2014; 6: 219ra8
- Schlegel NC, von Planta A, Widmer DS, Dummer R, Christofori G. PI3K signalling is required for a TGF β -induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells. *Exp Dermatol*. 2015; 24: 22-8
- Schoenewolf NL, Belloni B, Simcock M, Tonolla S, Vogt P, Scherrer E, Holzmann D, Dummer R. Clinical implications of distinct metastasizing preferences of different melanoma subtypes. *Eur J Dermatol* 2014; 24: 236-41
- Scholz M, Buder S, Kerl K, Dummer R, Garbe C. New Diagnostic Method for Lesions With Transepidermal Melanocytic Migration. *JAMA Dermatol* 2014; 150: 654-6
- Schweiger T, Kollmann D, Nikolowsky C, Traxler D, Guenova-Hötzenecker E, Lang G, Birner P, Klepetko W, Ankersmit HJ, Hoetzenecker K. Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking. *Eur J Cardiothorac Surg* 2014 46: 92-9
- Simon D, Eng PA, Borelli S, Kägi R, Schmid-Grendelmeier P. Gamma-linolenic acid levels correlate with clinical efficacy of evening primrose oil in patients with atopic dermatitis. *Adv Ther* 2014; 31: 180-8
- Skabytska Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen KM, Guenova E, Demircioglu D, Kempf WE, Volz T, Rammensee HG, Schaller M, Röcken M, Götz F, Biedermann T. Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells. *Immunity* 2014; 41: 762-75
- Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings G, Bachmann M. Preclinical efficacy and safety of an anti-IL-1 β vaccine for the treatment of type II diabetes. *Mol Ther Methods Clin Dev* 2014; 1: 14048
- Stimpfle DW, Serra AL, Wüthrich RP, French LE, Braun RP, Hofbauer GF. Spectrophotometric intracutaneous analysis: an investigation on photodamaged skin of immunocompromised patients. *J Eur Acad Dermatol Venereol*. 2015; 29: 1141-7
- Uermösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G, Kündig TM, Saudan P, Bachmann MF. IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. *Allergy* 2014; 69: 338-47
- Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zabel A, Moutouh-de Parseval L, Dummer R, Goldinger SM. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. *Ann Oncol* 2014; 25: 1437-41
- Urosevic-Maiwald M, Nobbe S, Kerl K, Benz R. Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: treatment- or disease-related? *J Dermatol*. 2014; 41: 329-33
- Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D; Dermatologic Cooperative Oncology Group of Germany (DeCOG). the genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. *Cancer Discov* 2014; 4: 94-109
- Volz T, Skabytska Y, Guenova-Hötzenecker E, Chen KM, Frick JS, Kirschning CJ, Kaesler S, Röcken M, Biedermann T. Non-pathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. *J Invest Dermatol* 2014; 134: 96-104
- von Moos S, Johansen P, Tay F, Graf N, Kündig TM, Senti G. Comparing safety of abrasion and tape-stripping as skin-preparation in allergen-specific epicutaneous immunotherapy. *J Allergy Clin Immunol* 2014;134: 965-967
- Voykov B, Deuter C, Zierhut M, Leitritz MA, Guenova-Hötzenecker E, Doycheva D. Is cyclophotocoagulation an option in the management of glaucoma secondary to Fuchs' uveitis syndrome? *Graefes Arch Clin Exp Ophthalmol* 2014; 252: 485-9
- Waeckerle-Men Y, Liang Y, von Moos S, Kündig TM, Johansen P. Multivalent paediatric allergy vaccines protect against allergic anaphylaxis in mice. *Clin Exp Allergy* 2014; 44: 429-437
- Wuethrich B., Borelli S, Geiges M., Lautenschlager S. Aus der Geschichte der Allergologie: Allergie im Selbstversuch - v.Pirquets Arm in der Moulagensammlung des Dermatologischen Ambulatoriums Stadtspital Triemli Zurich. *Allergologie* 2014; 37: 338-340
- Zabel F, Mohanan D, Bessa J, Link A, Fettelschoss A, Saudan P, Kündig TM, Bachmann MF. Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies. *J Immunol* 2014; 192: 5499-508
- Zaleska A, Eiwegger T, Soyer O, van de Veen W, Rhyner C, Soyka MB, Bekpen C, Demiröz D, Treis A, Söllner S, Palomares O, Kwok WW, Rose H, Senti G, Kündig TM, Ozoren N, Jutel M,

Akdis CA, Cramer R, Akdis M. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. *Allergy* 2014; 69: 1162-70

Zraggen S, Huggenberger R, Kerl K, Detmar M. An important role of the SDF-1/CXCR4 axis in chronic skin inflammation. *PLoS One* 2014; 9: e93665

Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalves M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. *Allergy* 2014; 69: 868-87

Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalves M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Nast A, Maurer M; Dermatology Section of the European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy* 2014; 69: e1-29

Reviews

Ballmer-Weber B et al. Mit Schutzcreme, Steroiden und Retinoiden die Haut beruhigen und den Beruf retten. Handekzem atopisch, irritativ, allergisch? *Schweiz Med Forum* 2013; 23: 453-8

Ballmer-Weber B, Hoffmann-Sommergruber K. Update: molekulare Diagnose der Gemüse- und Fruchallergie. *Allergo J Int* 2014; 23/1: 39-47

Ballmer-Weber B. Allergien – Eine frühe Abklärung lohnt sich. *Gesundheits-Partner Frühling* 2014: 4-7

Braun RP1, Marghoob A2. High-Dynamic-Range Dermoscopy Imaging and Diagnosis of Hypopigmented Skin Cancers. *JAMA Dermatol.* 2014 [Epub ahead of print]

Burg G, Geiges M: *Lepra vulgaris*. History of Psoriasis. *J Turk Acad Dermatol* 2014; 8: 1483 rl

Contassot E1, French LE1. New insights into acne pathogenesis: propionibacterium acnes activates the inflammasome. *J Invest Dermatol* 2014; 134: 310-3

Dreier J, Dummer R, Felderer L, Nägeli M, Gobbi S, Kunstfeld R. Emerging drugs and combination strategies for basal cell carcinoma. *Expert Opin Emerg Drugs* 2014; 19: 353-65

Dreier J, Hoetzenecker W, Fehrenbacher B, Schaller M, Guenova-Hötzenecker E. Autoantikörper greifen Integrität der Haut an. *Dermatologie Praxis* 2014; 24: 6-10

Dummer R. Precision medicine and skin cancer therapy: dealing with a moving target. Editorial. *Curr Opin Oncol* 2014; 26: 182-183

Espinosa E, Grob JJ, Dummer R, Rutkowski P, Robert C, Gogas H, Kefford R, Eggermont AM, Martin Algarra S, Hauschild A, Schadendorf D. Treatment Algorithms in Stage IV Melanoma. *Am J Ther* 2015; 22: 61-7

Gehrke S1, Otsuka A1, Huber R1, Meier B1, Kistowska M1, Fenini G1, Cheng P1, Dummer R1, Kerl K1, Contassot E2, French LE1. Metastatic melanoma cell lines do not secrete IL-1 β but promote IL-1 β production from macrophages. *J Dermatol Sci* 2014; 74: 167-9

Gnädinger M, Schmid-Grendelmeier P. Symptomatische Therapie der allergischen Rhinokonjunktivitis. *ARS MEDICI* 2014; 5: 277-82

Gräni NH, Läubli S. Wundbehandlung – Update 2014. *SZD* 2014; 2: 1-4

Guenova-Hötzenecker E, Hoetzenecker W. Wie lassen sich die Erscheinungsbilder richtig diagnostizieren und therapieren? *Dermatologie Praxis* 2014; 24: 1

Hofbauer GF1, Anliker M2, Boehncke WH3, Brand C4, Braun R5, Gaide O6, Hafner J1, Hunger R7, Itin P8, Kaeuper G9, Lautenschlager S10, Mainetti C11, Streit M12. Swiss clinical practice guidelines on field cancerization of the skin. *Swiss Med Wkly* 2014; 144: w14026

Hofbauer GF, Seçkin D, Gjersvik P, Bouwes Bavinck JN. Skin care in organ transplant patients europe meeting report from annual meeting, leiden, the Netherlands, 15-18 may 2014. *J Invest Dermatol* 2014; 134: 2861-3

Huber C1, French LE, Hafner J. Response to letter to the editor on skin manifestations of celiac disease: not always dermatitis herpetiformis. *Int J Dermatol* 2014; 53: e383-4

Jenny S, Ballmer-Weber BK. Der Ablauf einer Epikutantestung. *Praxis arena* 2014; 7: 12-15

- Jutel M, Papadopoulos NG, Gronlund H, Hoffman H-J, Schmid-Grendelmeier P et al. Recommendations for the allergy management in the primary care. *Allergy* 2014; 69: 708-18
- Kolm I, Barysch MJ, Nobbe S. Das Chamaeleon und die Erinnerungslücke. *Dermatologica Helvetica*. 2014; 26: 15-16
- Kolm I, Meli M, Nobbe S. Trigemintrophe Ulzera. *Dermatologica Helvetica* 2014; 26: 18-19
- Krämer I, Zabel F, Kündig TM, Johansen P. Transkutane Applikationen bei Impfungen und Immuntherapien. *Praxis* 2014; 103: 1247-1255
- Kündig TM, Johansen P, Bachmann MF, Cordell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. *J Allergy Clin Immunol* 2014; 133: 930-931
- Läuchli S. Tipps und Tricks für die Praxis. *Dermatologie Praxis* 2014; 24: 21-26
- Läuchli S. Es gibt keine schnellen Therapieerfolge in der Behandlung von Narben. *Dermatologie Praxis* 2014; 24: 2-3
- Läuchli S. Mohs-Chirurgie. Optimale Radikalität und Ästhetik in der Behandlung von Hauttumoren. *SZD* 2014; 4: 3-6
- Läuchli S, Riess C. Nagelextraktion ist „out“. *Der Allgemeinarzt* 2014; 8: 34-36
- Läuchli S, Riess C. Eingewachsene Zehennägel. *Ars Medici* 2014; 24: 1238-1240
- Meier B1, French LE1. [Autoinflammatory syndromes-cutaneous manifestations]. *Dtsch Med Wochenschr* 2014; 139: 1468-72
- Nobbe S. Kutane Vaskulitis – Übersicht für die Praxis. *Praxis Dermatologie* 2014; 24: 12-17
- Nobbe S, Kolm I, Maiwald M, Frauchiger B, French L, Cozzio A. Portrait Dermatologisches Ambulatorium Frauenfeld. *Dermatologica Helvetica* 2014; 26: 29
- Schmid-Grendelmeier P, Navarini A. Reisen und Haut. Veränderungen der Haut machen den Urlaub (leider) unvergesslich. *HAUSARZT PRAXIS* 2014; 9: 20-25
- Schmid-Grendelmeier P. Atopische Dermatitis und Pruritus im Alter. *DERMATOLOGIE PRAXIS* 2014; 2: 4
- Schmid-Grendelmeier P. Augen auf bei Insektenstichen. *Sprechstunde Doktor Stutz* 2014; 3: 16
- Schmid-Grendelmeier P. Global Allergy Forum and Second Davos Declaration 2013. Allergy: Barriers to cure – challenges and actions to be taken. *Allergy* 2014; 69: 978-82
- Schmid-Grendelmeier P. Topische Therapie der atopischen Dermatitis. Provokation und Hauttrockenheit vermeiden. *Dermatologie* 2014; 1: 6-8 / *SZD* 2014; 1: 15-6
- Schmid-Grendelmeier P. Tropische Dermatologie am Regional Dermatology Training Centre in Tanzania, Ostafrika. *Kongress Express* 2015; 115: 13
- Schmid-Grendelmeier P. Hoffnung für Patienten mit chronischer spontaner Urtikaria. *CongressSelection ARM MEDICI Mai* 2014: 15-16
- Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer HD. Caspase-1: the inflammasome and beyond. *Innate Immun* 2014; 20: 115-25
- Worm M, Jappe U, Kleine-Tebbe J, Schäfer C, Resse I, Saloga J., Treudler R, Zuberbier T, Wassmann A, Fuchs T, Dölle S, Raithe M, Ballmer-Weber B, Niggemann B, Werfel T. Nahrungsmittelallergie infolge immunologischer Kreuzreaktivitäten mit Inhalationsallergenen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie. *Allergo J Int* 2014; 23: 1-16.

University Hospital Zurich
Department of Dermatology
Gloriastrasse 31
8091 Zurich

Project Lead: Prof. Dr med. Lars E. French & Catherine Frey-Blanc
Contact: c.frey-blanc@usz.ch

www.dermatologie.unispital.ch
info@unispital.ch



**UniversitätsSpital
Zürich**

